271. 強直性脊椎炎 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 574 / 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
(+)-(S)-2-(6-methoxynaphthalen-2-yl) propanoic acid
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
2010 Phase 3 EUCTR2010-019872-65-GB Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2013 - EUCTR2010-019872-65-LT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-SK Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
2011 Phase 3 EUCTR2010-019872-65-CZ Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-BE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 - EUCTR2010-019872-65-AT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-HU Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-FI Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-EE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
- - EUCTR2010-019872-65-DE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
0881
Wyeth Farma S.A.
2006 - EUCTR2006-002349-35-ES Spain;
Wyeth Pharmaceuticals France, Wyeth Research Division
2007 - EUCTR2006-001061-42-FI Denmark;Finland;Sweden;United Kingdom;
2006 Phase 4 EUCTR2006-001061-42-GB Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-SE Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-DK Denmark;Finland;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
146368
Celgene Corporation
2021 Phase 2 EUCTR2019-004108-37-DE Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States;
18F]Fluoride
VU Medical Center, department of Rheumatology
2018 Phase 4 EUCTR2017-004850-40-NL Netherlands;
331731-18-1
Abbott
- - EUCTR2014-004532-18-Outside-EU/EEA Japan;
42942019
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
2016 Phase 4 EUCTR2016-002061-54-IT Italy;
5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
2010 Phase 3 EUCTR2010-019872-65-GB Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2013 - EUCTR2010-019872-65-LT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-SK Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
2011 Phase 3 EUCTR2010-019872-65-CZ Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-BE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 - EUCTR2010-019872-65-AT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-HU Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-FI Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-EE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
- - EUCTR2010-019872-65-DE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
5057732
AMC
2014 - EUCTR2013-002860-19-NL Netherlands;
99mTc-rhAnnexin V-128
Advanced Accelerator Applications
2014 Phase 1/Phase 2 NCT02328027 Switzerland;
ABT-494
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 3 EUCTR2019-003229-12-IT Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Ukraine;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2020 Phase 3 EUCTR2019-003229-12-SK Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003229-12-HU Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003229-12-GB Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003229-12-ES Argentina;Australia;Brazil;Canada;China;Hungary;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003229-12-DE Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-SE Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-NL Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-HR Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-DE Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-PT Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-PL Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-HU Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-GB Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-FR Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-FI Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-ES Australia;Canada;Hungary;Japan;Korea, Republic of;New Zealand;Portugal;Spain;Switzerland;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-DK Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-CZ Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-BE Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
ABY-035
Inmagene Biopharmaceuticals
2021 Phase 2 NCT04795141 Cayman Islands;
AIN457
NOVARTIS FARMA
2011 - EUCTR2010-024529-18-IT Belgium;Bulgaria;Canada;Germany;Italy;Mexico;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;
NOVARTIS FARMA S.P.A.
2015 Phase 3 EUCTR2013-005575-41-IT Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;United Kingdom;
Novartis Farma SpA
2013 Phase 3 EUCTR2013-001089-40-IT Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Novartis Farmacéutica, S.A.
2015 Phase 3 EUCTR2013-005575-41-ES Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001090-24-ES Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000046-35-ES Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
Novartis Pharma AG
2021 Phase 4 EUCTR2020-004284-98-GR Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;United States;
2021 Phase 4 EUCTR2020-004284-98-BG Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
2020 Phase 3 EUCTR2019-001177-90-SE Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
2020 Phase 3 EUCTR2019-001177-90-IT Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
2020 Phase 3 EUCTR2019-001177-90-GR Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
2020 Phase 3 EUCTR2019-001177-90-CZ Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
2020 Phase 3 EUCTR2019-001177-90-BG Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
- Phase 4 EUCTR2020-004284-98-PL Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
- Phase 4 EUCTR2020-004284-98-CZ Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
Novartis Pharma GmbH
2016 Phase 4 EUCTR2015-004575-74-DE Germany;
Novartis Pharma K.K.
2016 Phase 3 JPRN-JapicCTI-163241 -
Novartis Pharma Services AG
2016 Phase 3 EUCTR2015-005021-39-GB China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom;
2016 Phase 3 EUCTR2015-005021-39-CZ China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom;
2015 Phase 3 EUCTR2013-005575-41-SK Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-PL Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-NO Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-NL Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-GR Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-GB Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-FI Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-DK Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-DE Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-CZ Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-BG Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-AT Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001090-24-PT Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001090-24-NO Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001090-24-GR Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001090-24-GB Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001090-24-DE Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001090-24-BE Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001089-40-BG Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001089-40-BE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001090-24-CZ Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001089-40-NL Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001089-40-GB Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000046-35-NL Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000046-35-GB Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000046-35-FI Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000046-35-DE Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
2011 - EUCTR2010-024529-18-GB Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-DE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-BG Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-BE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2010 Phase 2 EUCTR2009-011591-30-GB Germany;Netherlands;United Kingdom;
2010 - EUCTR2009-011591-30-NL Germany;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011591-30-DE Germany;Netherlands;United Kingdom;
2009 - EUCTR2008-002631-33-NL Germany;Netherlands;United Kingdom;
2009 - EUCTR2008-002631-33-GB Germany;Netherlands;United Kingdom;
2008 - EUCTR2008-002631-33-DE Germany;Netherlands;United Kingdom;
Novartis Pharmaceuticals
2009 Phase 2 NCT00809159 Germany;Netherlands;United Kingdom;United States;
AIN457,
Novartis Pharma Services AG
2013 Phase 3 EUCTR2013-001089-40-DE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
AIN457A
Novartis Pharmaceuticals
2010 Phase 2 NCT01109940 Germany;Netherlands;United Kingdom;United States;
AIN457F
NOVARTIS FARMA
2012 Phase 3 EUCTR2012-000046-35-IT Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
ARCOXIA 90 mg comprimidos recubiertos con película
FUNDACIÓN ESPAÑOLA DE REUMATOLOGÍA (FER)
2010 - EUCTR2009-017309-12-ES Spain;
ARRY-371797
Array BioPharma Inc.
2009 - EUCTR2008-007510-30-PL Hungary;Poland;
2009 - EUCTR2008-007510-30-HU Hungary;Poland;
ARRY-371797, p38 inhibitor
Pfizer
2008 Phase 2 NCT00811499 Canada;United States;
AS
Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
2009 - ChiCTR-ONRC-11001565 -
Department of rheumatology of the Chinese PLA General Hospital
2015 - ChiCTR-IPR-15006753 China;
Guangdong Provincial Hospital of Chinese Medicine
2007 Phase 1 study ChiCTR-TRC-13004564 China;
PLA General Hospital
2018 - ChiCTR1800019227 China;
The First Affiliated Hospital of Suzhou University
2021 Phase 0 ChiCTR2100044377 China;
Abatacept
Charite University, Berlin, Germany
2008 Phase 2 NCT00558506 Germany;
Charité University Medicine
2007 - EUCTR2007-002967-28-DE Germany;
Aclasta
Cambridge University Hospitals NHS Foundation Trust
2007 - EUCTR2007-000087-25-GB United Kingdom;
Adalimumab
ABBOTT
2006 - EUCTR2005-004826-21-IT Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
AbbVie
2016 - NCT02750800 Hungary;
2014 - NCT02333383 Korea, Republic of;
2013 - NCT01768858 Austria;
Abbott
2010 Phase 3 NCT01114880 China;
2008 Phase 3 NCT00667355 Japan;
Abbott GmbH & Co. KG
2007 - EUCTR2005-004826-21-BE Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004826-21-DK Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-SE Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-IE Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-GR Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-GB Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-FI Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-ES Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-DE Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-AT Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
Abbott Japan Co., Ltd.
2008 Phase 3 JPRN-JapicCTI-080580 -
Abbott Laboratories
2006 - EUCTR2005-004826-21-NO Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
2008 - EUCTR2007-003358-27-DE Germany;
Chung Shan Medical University
2008 Phase 4 NCT02489760 Taiwan;
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly and Company
2021 Phase 3 NCT04527380 Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom;
2014 Phase 3 NCT01870284 Argentina;Belgium;Canada;Czech Republic;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Hvidovre University Hospital
2004 Phase 4 NCT00133315 Denmark;
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
Innovent Biologics (Suzhou) Co. Ltd.
2016 Phase 3 NCT02893254 -
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
Mianyang Hospital of Traditional Chinese Medicine
2021 Phase 4 ChiCTR2100044045 China;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Regionshospitalet Silkeborg
2010 Phase 4 NCT01174186 Denmark;
Universidade Nova de Lisboa
2015 Phase 4 NCT02492217 Portugal;
University Hospital, Tours
2013 Phase 4 NCT01895764 France;
Adalimumab (D2E7)
Abbott
2004 Phase 3 NCT00085644 United States;
2003 Phase 3 NCT00195819 Canada;United States;
Adalimumab (Humira)
Abbott
2006 Phase 3 NCT00478660 Austria;Belgium;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
Adalimumab 40 mg sc every other week
Charite University, Berlin, Germany
2005 Phase 2/Phase 3 NCT00235105 Germany;
Adalimumab and its biosimilars
Hanyang University Seoul Hospital
2022 Phase 4 NCT05164198 -
Adalimumab, Etanercept, Golimumab or infliximab
University Hospital, Montpellier
2012 - NCT01610947 France;
Alendronate
Göteborg University
2009 - NCT01104987 Sweden;
Anti TNF alpha agent
All India Institute of Medical Sciences, New Delhi
2011 - NCT01361542 India;
Anti TNF alpha therapy
All India Institute of Medical Sciences, New Delhi
2011 - NCT01361542 India;
Anti-(human tumor necrosis factor) immunoglobulin G (human-mouse monoclonal cA2 heavy chain)
Rheumazentrum Ruhrgebiet.
2006 Phase 4 EUCTR2005-002460-29-BE Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2005-002460-29-FI Belgium;Finland;Germany;United Kingdom;
2005 Phase 4 EUCTR2005-002460-29-GB Belgium;Finland;Germany;United Kingdom;
2005 - EUCTR2005-002460-29-DE Belgium;Finland;Germany;United Kingdom;
Anti-Human Interleukin-23 Monoclonal Antibody
SUN Pharmaceuticals Global FZE
2017 Phase 2 EUCTR2016-003936-19-HU Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003936-19-ES Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
Sun Pharma Global FZE
2018 Phase 3 EUCTR2018-001060-35-HU Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
2018 Phase 3 EUCTR2018-001060-35-ES Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
Anti-TNF
University Hospital, Bordeaux
2015 Phase 3 NCT02469753 France;Monaco;
Anti-TNF agents
Istanbul Physical Medicine Rehabilitation Training and Research Hospital
2019 - NCT04943237 Turkey;
Anti-TNF therapy (etanercept or adalimumab)
Imperial College London
2010 - NCT01060098 United Kingdom;
Anti-Tumor Necrosis Factor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
1999 Phase 2 NCT00000433 United States;
Apremilast
Celgene Corporation
2013 Phase 3 EUCTR2011-001555-37-EE Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-SK Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-SE Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-PL Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-NL Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-HU Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-GB Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-FR Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-ES Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-DE Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-CZ Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-BG Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-AT Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
Imperial College London
2009 Phase 2 NCT00944658 United Kingdom;
2009 - EUCTR2008-004229-40-GB United Kingdom;
Apremilast tablet 30 mg BID
Amgen
2012 Phase 3 NCT01583374 Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
BAT1406
Bio-Thera Solutions
2016 Phase 3 NCT04135508 -
BCD-055
Biocad
2016 Phase 3 NCT02762812 Russian Federation;
BCD-085
Biocad
2018 Phase 3 NCT03447704 Russian Federation;
2016 Phase 2 NCT02763111 -
BDMARD treatment
Uppsala University
2005 - NCT02840695 -
BI 655066 90 mg/ml
Boehringer Ingelheim
2014 Phase 2 EUCTR2013-003666-13-IT Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
Boehringer Ingelheim España, S.A.
2013 Phase 2 EUCTR2013-003666-13-ES Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
Boehringer Ingelheim Finland Ky
2013 Phase 2 EUCTR2013-003666-13-FI Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2014 Phase 2 EUCTR2013-003666-13-DE Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
Boehringer-Ingelheim bv
2014 Phase 2 EUCTR2013-003666-13-NL Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
SCS Boehringer Ingelheim Comm.V
2014 Phase 2 EUCTR2013-003666-13-BE Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
BI 730357
Boehringer Ingelheim RCV GmbH & Co KG
2020 Phase 2 EUCTR2019-001684-77-HU Belgium;Czechia;Georgia;Germany;Hungary;Korea, Republic of;Moldova, Republic of;Romania;Spain;Ukraine;United States;
BMS-188667
Charité University Medicine
2007 - EUCTR2007-002967-28-DE Germany;
BMS-986251
Bristol-Myers Squibb
2017 Phase 1/Phase 2 NCT03329885 Netherlands;
Bawei Shenqi Pill
Shanghai University of Traditional Chinese Medicine
2017 Phase 2/Phase 3 NCT04480359 China;
Bimekizumab
UCB Biopharma S.P.R.L.
2017 Phase 2 NCT03215277 Australia;Czechia;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2016 Phase 2 NCT02963506 Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States;
UCB Biopharma SPRL
2018 Phase 2 EUCTR2017-000957-37-NL Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-GR Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-DE Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-CZ Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2016-001102-42-GB Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001102-42-DE Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2017 Phase 2 EUCTR2016-001102-42-BG Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-001102-42-HU Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2016-001102-42-ES Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2016-001102-42-CZ Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
UCB Biopharma SRL
2020 Phase 3 NCT04436640 Belgium;Bulgaria;China;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 NCT03928743 Belgium;Bulgaria;China;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2017 Phase 2 NCT03355573 Bulgaria;Canada;Czechia;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States;
UCB Japan Co., Ltd
2019 Phase 3 JPRN-JapicCTI-194860 Japan, Asia except Japan, North America;
UCB Japan Co., Ltd.
2020 Phase 3 JPRN-JapicCTI-205414 Japan, Asia except Japan, North America, Europe;
Biologic DMARD
Seoul National University Hospital
2013 - NCT01965132 Korea, Republic of;
Biosimilar
McGill University Health Centre/Research Institute of the McGill University Health Centre
2018 - NCT03729674 Canada;
Opal Rheumatology Ltd.
2018 - NCT03470688 Australia;
Blood collection
CHU de Reims
2015 - NCT02809300 France;
Blood samples
Assistance Publique Hopitaux De Marseille
2017 - NCT03322618 France;
Blood sampling from infant
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood sampling from mother
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood sampling from umbilical cord
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Breast milk sampling
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02154425 France;Netherlands;Switzerland;United States;
CC-10004
Celgene Corporation
2013 Phase 3 EUCTR2011-001555-37-EE Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-SK Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-SE Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-PL Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-NL Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-HU Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-GB Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-FR Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-ES Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-DE Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-CZ Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-BG Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-AT Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
Imperial College London
2009 - EUCTR2008-004229-40-GB United Kingdom;
CC-99677
Celgene
2021 Phase 2 NCT04947579 Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States;
CC-99677 30mg Capsule
Celgene Corporation
2021 Phase 2 EUCTR2019-004108-37-DE Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States;
CC-99677 60mg Capsule
Celgene Corporation
2021 Phase 2 EUCTR2019-004108-37-DE Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States;
CDP870
SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
2010 Phase 3 EUCTR2009-011719-19-GB Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-FR Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
UCB BioSciences GmbH
2010 - EUCTR2009-011719-19-NL Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011719-19-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011719-19-CZ Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
UCB Biopharma SPRL
2018 Phase 2 EUCTR2017-000957-37-NL Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-GR Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-DE Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-CZ Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
CIMZIA certolizumab pegol 200 mg/ml solution for injection
UCB BIOSCIENCES GmbH
2016 Phase 3 EUCTR2015-001894-41-BG Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States;
2015 Phase 3 EUCTR2015-001894-41-HU Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States;
2015 Phase 3 EUCTR2015-001894-41-CZ Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States;
CNTO 148
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-GB Belgium;Finland;Germany;United Kingdom;
2006 Phase 3 EUCTR2004-003299-12-BE Belgium;Finland;Germany;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2004-003299-12-FI Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2004-003299-12-DE Belgium;Finland;Germany;United Kingdom;
CP-690,550
Pfizer Inc.
2018 Phase 3 EUCTR2018-000226-58-CZ Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 3 EUCTR2018-000226-58-HU Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-GB Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-FR Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-ES Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-DE Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-BG Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-AT Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
CP-690,550-10
Pfizer Inc, 235 East 42nd Street, New York 10017
2013 - EUCTR2011-005689-39-HU Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
Pfizer Inc. 235 East 42nd Street, New York, 10017
2014 Phase 2 EUCTR2011-005689-39-SK Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2014 - EUCTR2011-005689-39-NL Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
2014 - EUCTR2011-005689-39-DE Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2013 Phase 2 EUCTR2011-005689-39-ES Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2013 - EUCTR2011-005689-39-CZ Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
CT-P13
Pfizer
2015 - NCT02605642 Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Spain;United Kingdom;
CTLA4Ig
Charité University Medicine
2007 - EUCTR2007-002967-28-DE Germany;
Cannabidiol tablet
King Christian 10th Hospital for Rheumatology
2018 Phase 2 EUCTR2017-004226-15-DK Denmark;
Cannabis
University Hospital, Clermont-Ferrand
2020 - NCT04402554 France;
Celebrex
Charite Universitaetsmedizin
2016 Phase 4 EUCTR2016-000615-33-DE Germany;
Celecoxib
Affiliated Hospital of Nanjing University of Chinese Medicine
2021 Phase 0 ChiCTR2100044284 China;
Charite University, Berlin, Germany
2016 Phase 4 NCT02758782 Germany;
Columbia University
2018 Phase 4 NCT03473665 United States;
Guangdong Provincial Hospital of Chinese Medicine
2021 Phase 0 ChiCTR2100042789 China;
2007 Phase 1 study ChiCTR-TRC-13004564 China;
Jiangsu Province Hospital of TCM
2019 - ChiCTR2000034142 China;
Pfizer
2003 Phase 3 NCT00648141 Germany;
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009 Phase 3 NCT00762463 China;
Zhixiang Huang
2016 Phase 4 NCT02638896 -
Celecoxib 200 milligrams
Pfizer
2002 Phase 4 NCT02528201 Norway;
Celecoxib 400 milligrams
Pfizer
2002 Phase 4 NCT02528201 Norway;
Celecoxib, Celebrex®
Sun Yat-sen University
2012 - NCT01709656 China;
Certolizumab
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
Certolizumab pegol
READE
2015 - EUCTR2015-002284-42-FI Finland;
UCB Biopharma S.P.R.L.
2017 Phase 2 NCT03215277 Australia;Czechia;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
Certolizumab pegol (CZP)
SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
2010 Phase 3 EUCTR2009-011719-19-GB Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-FR Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
UCB BioSciences GmbH
2010 - EUCTR2009-011719-19-NL Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011719-19-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011719-19-CZ Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
Certolizumab pegol / CIMZIA
UCB Biosciences Inc.
2014 Phase 1 EUCTR2013-003812-30-NL France;Germany;Netherlands;Switzerland;United States;
Cimzia
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Cimzia 200 mg solution for injection
UCB Biopharma SPRL
2018 Phase 2 EUCTR2017-000957-37-NL Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-GR Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-DE Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-CZ Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
Cimzia®
SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
2010 Phase 3 EUCTR2009-011719-19-GB Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-FR Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
UCB BioSciences GmbH
2010 - EUCTR2009-011719-19-NL Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011719-19-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011719-19-CZ Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
Conventional therapy users for the last 5 years
Istanbul Physical Medicine Rehabilitation Training and Research Hospital
2019 - NCT04943237 Turkey;
Cosentyx
Rigshospitalet - Glostrup
Afdeling for Rygkirurgi, Led- og Bindevævssygdomme
Novartis Pharma AG
2021 Phase 4 EUCTR2020-004284-98-GR Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;United States;
2021 Phase 4 EUCTR2020-004284-98-BG Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
- Phase 4 EUCTR2020-004284-98-PL Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
- Phase 4 EUCTR2020-004284-98-CZ Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
Novartis Pharma GmbH
2016 Phase 4 EUCTR2015-004575-74-DE Germany;
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-001089-40-BE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
DMARDs
Janssen Research & Development, LLC
2015 - NCT02293681 China;
Diclofenac
Chinese PLA General Hospital
2010 Phase 1 study ChiCTR-ONRC-10000858 China;
Columbia University
2018 Phase 4 NCT03473665 United States;
Johnson & Johnson Taiwan Ltd
2008 Phase 4 NCT00766402 -
Pfizer
2003 Phase 3 NCT00648141 Germany;
Diclofenac 50 milligrams
Pfizer
2002 Phase 4 NCT02528201 Norway;
Diclofenac SR
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009 Phase 3 NCT00762463 China;
Diclophenac
Charite University, Berlin, Germany
2008 Phase 4 NCT00715091 Germany;
Dronabinol capsule
King Christian 10th Hospital for Rheumatology
2018 Phase 2 EUCTR2017-004226-15-DK Denmark;
Drug treatment
University of Zurich
2004 Phase 2 NCT01038011 Switzerland;
E-Device
UCB Biopharma S.P.R.L.
2017 Phase 3 NCT03357471 United States;
ENIA11
Mycenax Biotech Inc.
2016 Phase 3 NCT02685904 Taiwan;
Enbrel
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
Pfizer
2011 - NCT01411215 China;
2009 - NCT01421303 Belgium;
2008 - NCT01188655 -
READE
2015 - EUCTR2015-002284-42-FI Finland;
WYETH LEDERLE
2009 - EUCTR2007-003096-39-IT Italy;
2006 - EUCTR2005-001549-41-IT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Wyeth Farma S.A.
2006 - EUCTR2006-002349-35-ES Spain;
Wyeth Pharmaceuticals B.V.
2009 - EUCTR2009-015515-40-NL Netherlands;
Wyeth Pharmaceuticals France
2008 - EUCTR2006-002748-27-HU France;Germany;Hungary;Netherlands;
2007 - EUCTR2006-002748-27-NL France;Germany;Hungary;Netherlands;
2007 - EUCTR2006-002748-27-DE France;Germany;Hungary;Netherlands;
2006 Phase 4 EUCTR2006-002748-27-FR France;Germany;Hungary;Netherlands;
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Enbrel (Etanercept)
Wyeth is now a wholly owned subsidiary of Pfizer
2004 Phase 4 NCT00444340 -
Enbrel (etanercept)
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Wyeth is now a wholly owned subsidiary of Pfizer
2007 Phase 3 NCT00434044 -
2006 Phase 4 NCT00410046 Denmark;Finland;Sweden;United Kingdom;
2002 Phase 3 NCT00421915 -
Enbrel plus Celebrex
Sun Yat-sen University
2014 Phase 4 NCT01934933 China;
Enbrel®
Norfolk & Norwich University Hospitals NHS Foundation Trust
2010 Phase 4 EUCTR2010-020913-10-GB United Kingdom;
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
Entecavir
Seoul National University Hospital
2012 Phase 3 NCT01694264 Korea, Republic of;
Etanercept
Amgen
2002 Phase 3 NCT00356356 United States;
AryoGen Pharmed Co.
2014 - NCT04582084 Iran, Islamic Republic of;
Charite University, Berlin, Germany
2002 Phase 2 NCT01289743 Germany;
Chung Shan Medical University
2008 Phase 4 NCT02489760 Taiwan;
Hvidovre University Hospital
2004 Phase 4 NCT00133315 Denmark;
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
Nanfang Hospital of Southern Medical University
2019 - ChiCTR1900025749 China;
Norfolk & Norwich University Hospitals NHS Foundation Trust
2010 Phase 4 EUCTR2010-020913-10-GB United Kingdom;
Pfizer
2020 - NCT04507763 Iraq;
2014 - NCT02202850 Belgium;
2009 Phase 4 NCT00910273 Italy;
2007 - NCT00544557 Germany;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2016 Phase 2/Phase 3 NCT02809781 China;
Sun Yat-sen University
2007 Phase 4 NCT02915354 China;
WYETH LEDERLE
2009 - EUCTR2007-003096-39-IT Italy;
2006 - EUCTR2005-001549-41-IT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Wyeth Farma S.A.
2006 - EUCTR2006-002349-35-ES Spain;
Wyeth Pharmaceuticals France, Wyeth Research Division
2007 - EUCTR2006-001061-42-FI Denmark;Finland;Sweden;United Kingdom;
2006 Phase 4 EUCTR2006-001061-42-GB Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-SE Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-DK Denmark;Finland;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-CZ Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Wyeth is now a wholly owned subsidiary of Pfizer
2006 Phase 4 NCT00873730 -
2006 Phase 4 NCT00458185 -
2005 Phase 4 NCT00247962 Australia;Austria;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Qatar;Saudi Arabia;Spain;Sweden;Switzerland;United Kingdom;
2005 - NCT00195416 Korea, Republic of;
2004 Phase 3 NCT00418548 -
2002 Phase 3 NCT00421980 Belgium;
Etanercept (50mg per week)
Nanfang Hospital of Southern Medical University
2019 Phase 4 NCT04077957 China;
Etanercept (50mg per week, for 2 weeks)
Nanfang Hospital of Southern Medical University
2019 Phase 4 NCT04077957 China;
Etanercept (50mg per week, for 4 weeks)
Nanfang Hospital of Southern Medical University
2019 Phase 4 NCT04077957 China;
Etanercept (Enbrel)
Wyeth is now a wholly owned subsidiary of Pfizer
2007 Phase 4 NCT00420238 France;Germany;Hungary;Netherlands;
Etanercept (Full-Dose)
Zhixiang Huang
2016 Phase 4 NCT02638896 -
Etanercept (Half-Dose)
Zhixiang Huang
2016 Phase 4 NCT02638896 -
Etanercept and its biosimilars
Hanyang University Seoul Hospital
2022 Phase 4 NCT05164198 -
Etoricoxib
Organon and Co
2011 - NCT01327638 -
2009 - NCT01077843 -
2006 - NCT01685424 United States;
Spanish Foundation of Rheumatology
2010 Phase 3 NCT01091675 Spain;
Eupatilin
Seoul National University Boramae Hospital
2021 Phase 4 NCT04885751 -
Faecal microbiota transplantation
Torkell Ellingsen
2022 Phase 2 NCT04924270 -
Fengshigutong Capsule plus Imrecoxib
Sun Yat-sen University
2016 Phase 4 NCT03932006 China;
Filgotinib
Galapagos NV
2019 Phase 2 NCT03926195 Belgium;Bosnia and Herzegovina;Bulgaria;Czechia;Estonia;Georgia;Latvia;Poland;Spain;Ukraine;
2017 Phase 2 NCT03117270 Belgium;Bulgaria;Czechia;Estonia;Poland;Spain;Ukraine;
Gilead Sciences
2020 Phase 3 NCT04483700 -
2020 Phase 3 NCT04483687 -
Focetria (Monovalent MF59-Adjuvanted vaccine)
Tel-Aviv Sourasky Medical Center
2009 Phase 2 NCT01006681 -
GLPG0634
Galapagos NV
2019 Phase 2 EUCTR2018-003933-14-LV Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-ES Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-EE Bulgaria;Czech Republic;Estonia;Latvia;Poland;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-CZ Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-BG Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Czechia;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-BE Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2017 Phase 2 EUCTR2016-003636-21-ES Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
2017 Phase 2 EUCTR2016-003636-21-EE Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
2017 Phase 2 EUCTR2016-003636-21-CZ Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
2017 Phase 2 EUCTR2016-003636-21-BG Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
2017 Phase 2 EUCTR2016-003636-21-BE Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
GP2017
Novartis Farmacéutica, S.A.
2017 Phase 3 EUCTR2017-000679-10-ES Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
Novartis Pharma AG
2019 Phase 3 EUCTR2017-000679-10-GR Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-SK Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-PT Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-PL Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-NL Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-FR Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-CZ Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-GB Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-FI Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-DK Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-DE Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
GP2017 (adalimumab biosimilar)
Novartis Pharma K.K.
2018 Phase 3 JPRN-JapicCTI-184106 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Novartis Pharmaceuticals
2017 Phase 3 NCT03259074 Argentina;Australia;Belgium;Canada;Chile;Colombia;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
Ginger
Affiliated Hospital of Nanjing University of Chinese Medicine
2021 Phase 0 ChiCTR2100044284 China;
Gold
Dalian Blood Center
2018 - ChiCTR-DDD-17014196 China;
Golimumab
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-GB Belgium;Finland;Germany;United Kingdom;
Centocor, Inc.
2010 Phase 3 NCT01248793 China;
Charite University, Berlin, Germany
2016 Phase 4 NCT02758782 Germany;
Hanyang University Seoul Hospital
2022 Phase 4 NCT05164198 -
Janssen Biotech, Inc.
2009 - NCT01081717 United States;
Janssen Research & Development, LLC
2014 Phase 3 NCT02186873 Australia;Brazil;Canada;Germany;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Ukraine;United States;
Johnson & Johnson Private Limited
2019 Phase 4 NCT03733925 India;
Merck Sharp & Dohme Corp.
2012 Phase 4 NCT01668004 Netherlands;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Golimumab (CNTO 148)
Centocor, Inc.
2005 Phase 3 NCT00265083 Belgium;Canada;Finland;France;Germany;Korea, Republic of;Netherlands;Taiwan;United Kingdom;United States;
Golimumab Injection
MSD Pharmaceuticals LLC
2016 - NCT03557853 Russian Federation;
Golimumab Liquid in Vial
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-BE Belgium;Finland;Germany;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2004-003299-12-FI Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2004-003299-12-DE Belgium;Finland;Germany;United Kingdom;
Golimumab Pre-Filled Syringe
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-BE Belgium;Finland;Germany;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2004-003299-12-FI Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2004-003299-12-DE Belgium;Finland;Germany;United Kingdom;
Herpes Zoster Vaccine
University of Alabama at Birmingham
2016 Phase 2 NCT02538341 United States;
2013 Phase 2 NCT02538757 United States;
Human Anti-TNF IgG1 Monoclonal Antibody
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-GB Belgium;Finland;Germany;United Kingdom;
2006 Phase 3 EUCTR2004-003299-12-BE Belgium;Finland;Germany;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2004-003299-12-FI Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2004-003299-12-DE Belgium;Finland;Germany;United Kingdom;
Human Anti-TNFalfa
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-GB Belgium;Finland;Germany;United Kingdom;
2006 Phase 3 EUCTR2004-003299-12-BE Belgium;Finland;Germany;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2004-003299-12-FI Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2004-003299-12-DE Belgium;Finland;Germany;United Kingdom;
Human anti-TNFa monoclonal antibody
Janssen Biologics, BV
2014 Phase 3 EUCTR2014-000241-74-DE Australia;Brazil;Canada;Germany;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Ukraine;United States;
Human umbilical cord-derived MSCs
Shandong University
2011 Phase 1 NCT01420432 China;
Humira
Abbott GmbH & Co. KG
2007 - EUCTR2005-004826-21-BE Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004826-21-DK Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-SE Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-IE Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-GR Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-GB Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-FI Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-ES Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-DE Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-AT Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
Abbott Laboratories
2006 - EUCTR2005-004826-21-NO Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
Bio-Thera Solutions
2016 Phase 3 NCT04135508 -
Clinical Immunology and Rheumatology
2009 - EUCTR2008-006885-27-NL Netherlands;
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly and Company
2021 Phase 3 EUCTR2018-000681-10-CZ Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-GB Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DK Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Faculdade de Ciências Médicas da Universidade Nova de Lisboa
2014 Phase 4 EUCTR2013-004406-25-PT Portugal;
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Regionalhospital Silkeborg
2010 Phase 4 EUCTR2009-018085-35-DK Denmark;
Humira 40 mg/0.8 ml solution for injection
Abbott
- - EUCTR2014-004532-18-Outside-EU/EEA Japan;
Humira®
Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
2008 - EUCTR2007-003358-27-DE Germany;
Samsung Bioepis Co., Ltd.
2014 Phase 3 EUCTR2013-005013-13-BG Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-PL Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-LT Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
Hydroxychloroquine
Nanfang Hospital of Southern Medical University
2019 Phase 4 NCT04077957 China;
Hyrimoz
Novartis Pharma AG
2019 Phase 3 EUCTR2017-000679-10-GR Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-SK Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-PT Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-PL Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-NL Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-CZ Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-FI Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-DK Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-DE Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
IBI303
Innovent Biologics (Suzhou) Co. Ltd.
2016 Phase 3 NCT02893254 -
Ibuprofen
School of Chinese Medicine Southern Medical University
2010 - ChiCTR-TRC-11001274 China;
Iguratimod
PLA General Hospital
2018 - ChiCTR1800019227 China;
Qilu Hospital of Shandong University
2021 Phase 4 ChiCTR2100043171 China;
Ilumetri
Sun Pharma Global FZE
2018 Phase 3 EUCTR2018-001060-35-HU Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
Indomethacin
Boehringer Ingelheim
2001 Phase 3 NCT02183168 -
Columbia University
2018 Phase 4 NCT03473665 United States;
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
2011 Phase 1+Phase 2 ChiCTR-TRC-11001417 China;
Infliximab
Association de Recherche Clinique en Rhumatologie
2003 Phase 3 NCT00439283 France;
Celltrion
2012 Phase 1 NCT01571206 Korea, Republic of;
2010 Phase 1 NCT01220518 Korea, Republic of;
Centocor, Inc.
2002 Phase 3 NCT00207701 -
Chiba University Hospital
2012 Phase 2 JPRN-UMIN000015297 Japan;
2012 Phase 2 JPRN-UMIN000007806 Japan;
Gu Jieruo
2008 Phase 4 NCT00936143 China;
Göteborg University
2003 - NCT01850121 Sweden;
Hvidovre University Hospital
2004 Phase 4 NCT00133315 Denmark;
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
Janssen Korea, Ltd., Korea
2007 - NCT00760669 Korea, Republic of;
2007 - NCT00724529 Korea, Republic of;
Janssen Research & Development, LLC
2015 - NCT02293681 China;
Merck Sharp & Dohme Corp.
2010 Phase 4 NCT01148901 Spain;
2009 Phase 3 NCT00844805 Austria;Belgium;Denmark;France;Germany;Hungary;Korea, Republic of;Russian Federation;Ukraine;United States;
2005 Phase 3 NCT00202865 Canada;
2004 Phase 4 NCT00779012 -
2004 - NCT00725543 -
2003 - NCT00818168 Germany;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Rheumazentrum Ruhrgebiet
2005 - NCT00237419 Belgium;Finland;France;Germany;Netherlands;United Kingdom;
Rheumazentrum Ruhrgebiet.
2006 Phase 4 EUCTR2005-002460-29-BE Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2005-002460-29-FI Belgium;Finland;Germany;United Kingdom;
2005 Phase 4 EUCTR2005-002460-29-GB Belgium;Finland;Germany;United Kingdom;
2005 - EUCTR2005-002460-29-DE Belgium;Finland;Germany;United Kingdom;
Schering-Plough France
2008 - EUCTR2006-001579-40-DK Denmark;France;Hungary;Spain;
2007 Phase 4 EUCTR2006-001579-40-HU Denmark;France;Hungary;Spain;
2007 Phase 4 EUCTR2006-001579-40-FR Denmark;France;Hungary;Spain;
2007 - EUCTR2006-001579-40-ES Denmark;France;Hungary;Spain;
University Hospital, Tours
2007 Phase 4 NCT00507403 France;
Infliximab (BCD-055)
Biocad
2015 Phase 1 NCT02359903 Belarus;Russian Federation;
Infliximab (Remicade)
Biocad
2015 Phase 1 NCT02359903 Belarus;Russian Federation;
Infliximab and MTX
Chinese University of Hong Kong
2005 Phase 4 NCT00432432 -
Infliximab biosimilar
Hanyang University Seoul Hospital
2022 Phase 4 NCT05164198 -
Intravenous infusion of MSCs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2016 Phase 2/Phase 3 NCT02809781 China;
Ixekizumab
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly & Company
2013 Phase 3 EUCTR2011-002325-22-GB Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-HU Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-ES Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-DE Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-BE Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Eli Lilly and Company
2021 Phase 3 NCT04527380 Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom;
2014 Phase 3 NCT01870284 Argentina;Belgium;Canada;Czech Republic;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
JS005
Shanghai Junshi Bioscience Co., Ltd.
2021 Phase 2 NCT05212051 China;
Jaktinib Hydrochloride Tablets
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020 Phase 2 NCT04507659 -
Jing Si Herbal Tea LIQUID PACKETS
Buddhist Tzu Chi General Hospital
2022 - NCT05257174 Taiwan;
KIN-1901
Kinevant Sciences GmbH
2019 Phase 1 NCT04205851 Canada;
Kunxian capsule
Gu Jieruo
2008 Phase 4 NCT00953979 China;
L04AA24
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
L04AB01
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
L04AB04
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
L04AB05
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
LSD
Universidade do Porto
2020 - NCT04386538 Portugal;
LY2439821
Eli Lilly & Company
2013 Phase 3 EUCTR2011-002325-22-GB Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-HU Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-ES Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-DE Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-BE Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Eli Lilly and Company
2021 Phase 3 EUCTR2018-000681-10-CZ Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-GB Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DK Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Leflunomide
The First Affiliated Hospital of Heilongjiang Chinese Medicine Colledge
2018 - ChiCTR-INR-17013574 China;
Loxoprofen sodium hydrogel patch
Sun Yat-sen University
2015 Phase 4 NCT03800797 China;
Loxoprofen sodium tablet
Sun Yat-sen University
2015 Phase 4 NCT03800797 China;
Lyophilized etanercept powder(Yisaipu)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2014 Phase 3 NCT04345458 China;
METHOTREXATE DISODIUM
CHRU de TOURS
2013 Phase 4 EUCTR2012-004939-23-FR France;
METOJECT
CHRU de TOURS
2013 Phase 4 EUCTR2012-004939-23-FR France;
MK-0663
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
2010 Phase 3 EUCTR2010-019872-65-GB Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2013 - EUCTR2010-019872-65-LT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-SK Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
2011 Phase 3 EUCTR2010-019872-65-CZ Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-BE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 - EUCTR2010-019872-65-AT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-HU Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-FI Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-EE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
- - EUCTR2010-019872-65-DE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
MK-3222
SUN Pharmaceuticals Global FZE
2017 Phase 2 EUCTR2016-003936-19-HU Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003936-19-ES Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
Sun Pharma Global FZE
2018 Phase 3 EUCTR2018-001060-35-HU Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
2018 Phase 3 EUCTR2018-001060-35-ES Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
MRNA COVD19 vaccine
Mayo Clinic
2021 Early Phase 1 NCT04839315 United States;
MSB11022
Fresenius Kabi SwissBioSim GmbH
2019 Phase 1 NCT04018599 United States;
MSC
Sun Yat-sen University
2012 - NCT01709656 China;
MTX
Department of rheumatology of the Chinese PLA General Hospital
2015 - ChiCTR-IPR-15006753 China;
MabThera 500
University Hospital of North Staffordshire
2006 Phase 2 EUCTR2005-005358-27-GB United Kingdom;
Meloxicam
Columbia University
2018 Phase 4 NCT03473665 United States;
Shanghai University of Traditional Chinese Medicine
2017 Phase 2/Phase 3 NCT04480359 China;
Meloxicam suppository
Boehringer Ingelheim
2001 Phase 3 NCT02183168 -
Meloxicam tablet
Boehringer Ingelheim
2001 Phase 3 NCT02183168 -
Methotrexate
Association de Recherche Clinique en Rhumatologie
2003 Phase 3 NCT00439283 France;
Charite University, Berlin, Germany
2003 Phase 2 NCT00243750 Germany;
Janssen Korea, Ltd., Korea
2007 - NCT00760669 Korea, Republic of;
Merck Sharp & Dohme Corp.
2010 - NCT01313858 Germany;
Nanfang Hospital of Southern Medical University
2019 Phase 4 NCT04077957 China;
University Hospital, Tours
2013 Phase 4 NCT01895764 France;
Methylprednisolone
Saratov State Medical University
2012 Phase 2 NCT01790022 Russian Federation;
Misoprostol
Korea Otsuka Pharmaceutical Co.,Ltd.
2007 Phase 3 NCT00576706 Korea, Republic of;
Monoclonal Antibody (MAb)
Eli Lilly & Company
2013 Phase 3 EUCTR2011-002325-22-GB Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-HU Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-ES Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-DE Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-BE Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Méthotrexate Bellon Comprimé
CHRU-TOURS
2007 - EUCTR2006-005157-29-FR France;
N.A.
Boehringer Ingelheim
2014 Phase 2 EUCTR2013-003666-13-IT Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
NSAIDs
Janssen Research & Development, LLC
2015 - NCT02293681 China;
University Hospital, Bordeaux
2015 Phase 3 NCT02469753 France;Monaco;
NSAIDs and sulfasalazine
Chung Shan Medical University
2009 Phase 2 NCT02456363 Taiwan;
Nanocurcumin
Tabriz University of Medical Sciences
2017 Phase 2 NCT03140657 Iran, Islamic Republic of;
Naprosyn
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
2010 Phase 3 EUCTR2010-019872-65-GB Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2013 - EUCTR2010-019872-65-LT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-SK Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
2011 Phase 3 EUCTR2010-019872-65-CZ Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-BE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 - EUCTR2010-019872-65-AT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-HU Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-FI Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-EE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
- - EUCTR2010-019872-65-DE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Naprosysn
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
2010 Phase 3 EUCTR2010-019872-65-GB Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2010-019872-65-CZ Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-BE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 - EUCTR2010-019872-65-AT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-HU Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-FI Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-EE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
- - EUCTR2010-019872-65-DE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Naproxen
Merck Sharp & Dohme Corp.
2009 Phase 3 NCT00844805 Austria;Belgium;Denmark;France;Germany;Hungary;Korea, Republic of;Russian Federation;Ukraine;United States;
Naproxen 500 mg tablets (PN 200 minus omeprazole)
POZEN
2006 Phase 3 NCT00367211 United States;
Non-anti-TNF biologics
Janssen Biotech, Inc.
2009 - NCT01081717 United States;
None
Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
2009 - ChiCTR-ONRC-11001565 -
Normal saline
Inmagene Biopharmaceuticals
2021 Phase 2 NCT04795141 Cayman Islands;
NsNSAIDs
Organon and Co
2011 - NCT01327638 -
Observational study
Janssen Korea, Ltd., Korea
2007 - NCT00760669 Korea, Republic of;
Olsalazine
National Center for Research Resources (NCRR)
1996 Phase 2 NCT00004288 -
Oral
Pfizer
2008 Phase 2 NCT00811499 Canada;United States;
Orencia
Charité University Medicine
2007 - EUCTR2007-002967-28-DE Germany;
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
Originator
Opal Rheumatology Ltd.
2018 - NCT03470688 Australia;
Originator (legacy) drug
McGill University Health Centre/Research Institute of the McGill University Health Centre
2018 - NCT03729674 Canada;
Other COX-2 inhibitor
Organon and Co
2011 - NCT01327638 -
Other Cox-2 inhibitors
Organon and Co
2009 - NCT01077843 -
Other Non-selective NSAIDs
Organon and Co
2009 - NCT01077843 -
Oxygen
Shenzhen Second People's Hospital
2021 - ChiCTR2100042477 China;
PN 200 tablets (500 mg naproxen and 20 mg omeprazole)
POZEN
2006 Phase 3 NCT00367211 United States;
Pamidronate
Bnai Zion Medical Center
2014 Phase 4 NCT02313727 Israel;
Parecoxib
Peking Union Medical College Hospital
2014 - ChiCTR1800014846 China;
Part I - etoricoxib
Organon and Co
2010 Phase 3 NCT01208207 Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Part I- naproxen
Organon and Co
2010 Phase 3 NCT01208207 Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Part II- etoricoxib
Organon and Co
2010 Phase 3 NCT01208207 Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Part II- naproxen
Organon and Co
2010 Phase 3 NCT01208207 Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Placebo
UCB Japan Co., Ltd
2019 Phase 3 JPRN-JapicCTI-194860 Japan, Asia except Japan, North America;
Prednisolone
Charite University, Berlin, Germany
2002 Phase 2/Phase 3 NCT00244166 Germany;
Prefilled liquid etanercept(Yisaipu)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2014 Phase 3 NCT04345458 China;
REMICADE 100 mg polvo para concentrado para solución para perfusión
Schering Plough, S.A
2010 - EUCTR2009-016587-36-ES Spain;
REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
2016 Phase 4 EUCTR2016-002061-54-IT Italy;
ROACTEMRA 20 mg/ml, concentrado para solución para perfusión
F. Hoffmann-La Roche Ltd.
2010 - EUCTR2009-017488-40-ES Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-ES Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
RTNV148B IgG
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-GB Belgium;Finland;Germany;United Kingdom;
2006 Phase 3 EUCTR2004-003299-12-BE Belgium;Finland;Germany;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2004-003299-12-FI Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2004-003299-12-DE Belgium;Finland;Germany;United Kingdom;
Rebamipide
Korea Otsuka Pharmaceutical Co.,Ltd.
2007 Phase 3 NCT00576706 Korea, Republic of;
Seoul National University Boramae Hospital
2021 Phase 4 NCT04885751 -
Recombinant TNF-a receptor: IgG Fc fusion protein
Zhejiang Hisun Pharmaceutical Co. Ltd.
2018 - NCT03636984 -
Recombinant human monoclonal antibody to Il-17 of the IgG1-k-class
Novartis Pharma Services AG
2010 Phase 2 EUCTR2009-011591-30-GB Germany;Netherlands;United Kingdom;
2010 - EUCTR2009-011591-30-NL Germany;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011591-30-DE Germany;Netherlands;United Kingdom;
2009 - EUCTR2008-002631-33-NL Germany;Netherlands;United Kingdom;
2009 - EUCTR2008-002631-33-GB Germany;Netherlands;United Kingdom;
2008 - EUCTR2008-002631-33-DE Germany;Netherlands;United Kingdom;
Remicade
Merck Sharp & Dohme Corp.
2005 Phase 4 NCT00778869 -
2004 Phase 4 NCT00779935 -
READE
2015 - EUCTR2015-002284-42-FI Finland;
Rheumazentrum Ruhrgebiet.
2006 Phase 4 EUCTR2005-002460-29-BE Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2005-002460-29-FI Belgium;Finland;Germany;United Kingdom;
2005 Phase 4 EUCTR2005-002460-29-GB Belgium;Finland;Germany;United Kingdom;
2005 - EUCTR2005-002460-29-DE Belgium;Finland;Germany;United Kingdom;
Schering-Plough France
2008 - EUCTR2006-001579-40-DK Denmark;France;Hungary;Spain;
2007 Phase 4 EUCTR2006-001579-40-HU Denmark;France;Hungary;Spain;
2007 Phase 4 EUCTR2006-001579-40-FR Denmark;France;Hungary;Spain;
2007 - EUCTR2006-001579-40-ES Denmark;France;Hungary;Spain;
Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning
Diakonhjemmet Hospital AS
2014 - EUCTR2014-002056-40-NO Norway;
Remicade®
Biocad
2016 Phase 3 NCT02762812 Russian Federation;
Remsima 100 mg pulver til konsentrat til infusjonsvæske, oppløsning
Diakonhjemmet Hospital AS
2014 - EUCTR2014-002056-40-NO Norway;
RhuTNFR:Fc
Wyeth Pharmaceuticals France, Wyeth Research Division
2007 - EUCTR2006-001061-42-FI Denmark;Finland;Sweden;United Kingdom;
2006 Phase 4 EUCTR2006-001061-42-GB Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-SE Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-DK Denmark;Finland;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-CZ Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Rinvoq
AbbVie Deutschland GmbH & Co. KG
2020 Phase 3 EUCTR2019-003229-12-SK Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Risankizumab
AbbVie
2014 Phase 2 NCT02047110 Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
Rituximab
Charite University, Berlin, Germany
2007 Phase 2/Phase 3 NCT00432653 Germany;
Rituximab/ Mabthera
Charité Universitaetsmedizin
2006 - EUCTR2006-002306-64-DE Germany;
Ro 487-533/F01
F. Hoffmann-La Roche Ltd.
2011 Phase 3 EUCTR2009-017488-40-BE Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-017488-40-GB Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-SK Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-DK Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-DE Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-CZ Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-BG Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
Ro 487-5733/F01
F. Hoffmann-La Roche Ltd.
2011 Phase 2;Phase 3 EUCTR2009-017443-34-BE Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2011 - EUCTR2009-017443-34-DE Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
2011 - EUCTR2009-017443-34-BG Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 Phase 2;Phase 3 EUCTR2009-017443-34-GB Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-SK Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-CZ Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
Ro 487-7533/F01
F. Hoffmann-La Roche Ltd.
2010 - EUCTR2009-017488-40-LT Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-LT Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
Ro45-2294
Charité Universitaetsmedizin
2006 - EUCTR2006-002306-64-DE Germany;
RoActemra
F. Hoffmann-La Roche Ltd.
2010 - EUCTR2009-017488-40-IT Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-IT Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
RoActemra®
F. Hoffmann-La Roche Ltd.
2011 Phase 3 EUCTR2009-017488-40-BE Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2009-017443-34-BE Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2011 - EUCTR2009-017443-34-DE Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
2011 - EUCTR2009-017443-34-BG Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-017488-40-GB Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 Phase 2;Phase 3 EUCTR2009-017443-34-GB Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-SK Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-LT Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-DK Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-DE Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-CZ Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-BG Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-SK Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-LT Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-CZ Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
Rosuvastatin
Diakonhjemmet Hospital
2013 - NCT01389388 Norway;
SAR153191
Sanofi-aventis Recherche & Développement
2010 Phase 2 EUCTR2009-016068-35-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 Phase 2 EUCTR2009-016068-35-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-NL Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-LT Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
sanofi-aventis Recherche & Développement
2010 Phase 3 EUCTR2010-019263-11-FR Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
2010 Phase 3 EUCTR2010-019263-11-ES Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
2010 Phase 3 EUCTR2010-019263-11-BE Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
2010 - EUCTR2010-019263-11-LT Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
2010 - EUCTR2010-019263-11-HU Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
2010 - EUCTR2010-019263-11-CZ Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
2010 - EUCTR2010-019263-11-AT Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
SB4 (etanercept biosimilar)
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
SB5
Samsung Bioepis Co., Ltd
2015 - EUCTR2014-004887-39-PL Poland;
Samsung Bioepis Co., Ltd.
2014 Phase 3 EUCTR2013-005013-13-BG Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-PL Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-LT Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
SHR-1314
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2021 Phase 2/Phase 3 NCT04840485 China;
SHR0302
Jiangsu HengRui Medicine Co., Ltd.
2020 Phase 2/Phase 3 NCT04481139 China;
SUNPG1622 I dose
Sun Pharmaceutical Industries Limited
2017 Phase 2 NCT02980705 Hungary;Poland;Spain;United States;
Salicylazosulfapyridine
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
2011 Phase 1+Phase 2 ChiCTR-TRC-11001417 China;
Sarilumab
Sanofi
2010 Phase 2 NCT01118728 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Lithuania;Netherlands;Poland;Spain;United States;
2010 Phase 2 NCT01061723 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Lithuania;Netherlands;Poland;Spain;Turkey;United States;
Secukinumab
NOVARTIS FARMA
2011 - EUCTR2010-024529-18-IT Belgium;Bulgaria;Canada;Germany;Italy;Mexico;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;
Novartis Farma SpA
2013 Phase 3 EUCTR2013-001089-40-IT Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Novartis Pharma K.K.
2018 Phase 3 JPRN-JapicCTI-184106 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-001089-40-BG Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001089-40-NL Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001089-40-GB Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001089-40-DE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-GB Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-DE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-BG Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-BE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Novartis Pharmaceuticals
2022 - NCT05155098 -
2019 Phase 3 NCT04156620 Belgium;Brazil;Bulgaria;Colombia;Czechia;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
2017 Phase 3 NCT03259074 Argentina;Australia;Belgium;Canada;Chile;Colombia;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2016 Phase 3 NCT02896127 China;Czech Republic;Czechia;Korea, Republic of;United Kingdom;
2015 Phase 3 NCT02159053 Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2014 Phase 3 NCT02008916 Belgium;Czech Republic;Czechia;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 NCT01863732 Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Secukinumab (150 mg)
Novartis Pharmaceuticals
2012 Phase 3 NCT01649375 Austria;Canada;Czech Republic;Czechia;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
2011 Phase 3 NCT01358175 Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Secukinumab (75 mg)
Novartis Pharmaceuticals
2012 Phase 3 NCT01649375 Austria;Canada;Czech Republic;Czechia;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
2011 Phase 3 NCT01358175 Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Secukinumab (AIN457) 150 mg s.c.
Novartis Pharmaceuticals
2016 Phase 4 NCT02763046 Germany;
Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
Novartis Pharmaceuticals
2016 Phase 3 NCT02750592 Japan;
Secukinumab 150 mg/1 ml Solution for injection
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-001089-40-BE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Secukinumab 150 milligram [Cosentyx]
Professor Mikkel Østergaard
2019 Phase 4 NCT03639740 Denmark;
Secukinumab 75 mg/0.5 ml Solution for injection
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-001089-40-BE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Simponi
Charite Universitaetsmedizin
2016 Phase 4 EUCTR2016-000615-33-DE Germany;
Chinese University of Hong Kong
2010 Phase 4 NCT01212653 China;
MERCK SHARP & DOHME B.V.
2012 Phase 4 EUCTR2012-002458-21-NL Netherlands;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Simponi®
Merck Sharp & Dohme Corp.
2010 - NCT01313858 Germany;
Sodium chloride
Chinese University of Hong Kong
2010 Phase 4 NCT01212653 China;
Stelara
Charité Universitätsmedizin Berlin
2011 Phase 2 EUCTR2011-000844-56-DE Germany;
Sulfasalazine
Nanchang Hongdu Hospital of TCM
2020 - ChiCTR2000038277 China;
Nanfang Hospital of Southern Medical University
2019 Phase 4 NCT04077957 China;
School of Chinese Medicine Southern Medical University
2010 - ChiCTR-TRC-11001274 China;
Sun Yat-sen University
2008 Phase 2/Phase 3 NCT00889694 -
WYETH LEDERLE
2006 - EUCTR2005-001549-41-IT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Zhixiang Huang
2016 Phase 4 NCT02638896 -
Sulfasalazine, SSZ
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-CZ Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Sulphasalazine (SSZ)
Wyeth is now a wholly owned subsidiary of Pfizer
2005 Phase 4 NCT00247962 Australia;Austria;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Qatar;Saudi Arabia;Spain;Sweden;Switzerland;United Kingdom;
Sulphasalazine 500 mg En-Tabs
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-CZ Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Systemic non-biological treatments
Janssen Biotech, Inc.
2009 - NCT01081717 United States;
TA-650 (Infliximab)
Mitsubishi Tanabe Pharma Corporation
- Phase 3 JPRN-JapicCTI-070346 -
THA
99 Huaihai Road West, Xuzhou, Jiangsu, China
2019 - ChiCTR1900025635 China;
TNF alpha
Chung Shan Medical University
2009 Phase 2 NCT02456363 Taiwan;
TNF blockers (infliximab, adalimumab, etanercept)
University of Sao Paulo
2008 Phase 4 NCT01072058 Brazil;
TNF-a antagonists, non-TNFs, DMARD non-biologics
Biologics & Biosimilars Collective Intelligence Consortium
2012 - NCT02922192 -
TNF-alpha antagonists
Assistance Publique - Hôpitaux de Paris
2004 - NCT00224562 France;
TNF-inhibition
Region Skane
2019 - NCT03839862 Sweden;
TNFR:Fc
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
Wyeth Pharmaceuticals France, Wyeth Research Division
2007 - EUCTR2006-001061-42-FI Denmark;Finland;Sweden;United Kingdom;
2006 Phase 4 EUCTR2006-001061-42-GB Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-SE Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-DK Denmark;Finland;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-CZ Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
TNR-001
Wyeth Pharmaceuticals France, Wyeth Research Division
2007 - EUCTR2006-001061-42-FI Denmark;Finland;Sweden;United Kingdom;
2006 Phase 4 EUCTR2006-001061-42-GB Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-SE Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-DK Denmark;Finland;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-CZ Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
TNR-001, TNFR:FC
Wyeth Farma S.A.
2006 - EUCTR2006-002349-35-ES Spain;
TOFACITINIB CITRATE
Pfizer Inc, 235 East 42nd Street, New York 10017
2013 - EUCTR2011-005689-39-HU Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
Pfizer Inc.
2018 Phase 3 EUCTR2018-000226-58-CZ Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc. 235 East 42nd Street, New York, 10017
2014 Phase 2 EUCTR2011-005689-39-SK Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2014 - EUCTR2011-005689-39-NL Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
2014 - EUCTR2011-005689-39-DE Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2013 Phase 2 EUCTR2011-005689-39-ES Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2013 - EUCTR2011-005689-39-CZ Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 3 EUCTR2018-000226-58-HU Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-GB Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-FR Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-ES Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-DE Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-BG Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-AT Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Taltz (80 mg solution for injection in pre-filled syringe)
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly and Company
2021 Phase 3 EUCTR2018-000681-10-CZ Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-GB Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DK Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Tapering or discontinuation of etanercept
Second Affiliated Hospital, School of Medicine, Zhejiang University
2012 - NCT03880968 -
Technetium labelled glucosamine
University of Sydney
2012 - NCT01789151 Australia;
Terbinafine Tablets
Oregon Health and Science University
2021 Early Phase 1 NCT05119712 United States;
Thalidomide
Chinese PLA General Hospital
2010 Phase 1 study ChiCTR-ONRC-10000858 China;
Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
2009 - ChiCTR-ONRC-11001846 -
Shanghai Pharmaceuticals Holding Co., Ltd
2013 Phase 2 NCT02201043 China;
The General Hospital of People's Liberation Army
2013 Phase 2 study ChiCTR-TRC-13003449 China;
Tildrakizumab
SUN Pharmaceuticals Global FZE
2017 Phase 2 EUCTR2016-003936-19-HU Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003936-19-ES Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
Tildrakizumab 100 mg/ml
Sun Pharma Global FZE
2018 Phase 3 EUCTR2018-001060-35-HU Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
2018 Phase 3 EUCTR2018-001060-35-ES Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
Tocilizumab
F. Hoffmann-La Roche Ltd.
2010 - EUCTR2009-017488-40-LT Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-IT Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-LT Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
Hoffmann-La Roche
2010 Phase 3 NCT01209702 Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;India;Italy;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
2010 Phase 3 NCT01209689 Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;India;Italy;Lithuania;Netherlands;Poland;Slovakia;South Africa;Spain;United Kingdom;United States;
Tofacitinib
Pfizer
2018 Phase 3 NCT03502616 Australia;Bulgaria;Canada;China;Czechia;France;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United States;
2013 Phase 2 NCT01786668 Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States;
Tofacitinib XR
Pfizer
2021 - NCT04876781 -
Total Glucosides Paeony Capsules
Sun Yat-sen University
2011 Phase 4 NCT01517620 China;
Tramadol /acetaminophen
Johnson & Johnson Taiwan Ltd
2008 Phase 4 NCT00766402 -
Tripterygium
Sun Yat-sen University
2008 Phase 2/Phase 3 NCT00889694 -
Tripterygium Wilfordii
Jiangsu Provincial Hospital of Traditional Chinese Medicine
2011 - ChiCTR-TRC-11001193 China;
UCB4940
UCB BIOPHARMA SRL
2018 Phase 2 EUCTR2017-001002-15-DE Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States;
UCB BIOSCIENCES GmbH
2017 Phase 2 EUCTR2017-001002-15-HU Hungary;
UCB Biopharma SPRL
2019 Phase 3 EUCTR2017-003065-95-FR Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-ES Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-000957-37-NL Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-001002-15-ES Germany;Hungary;Spain;
2017 Phase 2 EUCTR2017-000957-37-GR Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-DE Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-CZ Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2016-001102-42-GB Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001102-42-DE Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2017 Phase 2 EUCTR2016-001102-42-BG Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-001102-42-HU Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2016-001102-42-ES Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2016-001102-42-CZ Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
UCB Biopharma SRL
2020 Phase 3 EUCTR2019-004163-47-HU Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004163-47-GB Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004163-47-DE Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004163-47-CZ Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004163-47-BG Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-NL Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-HU Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-GB Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-DE Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-CZ Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-BG Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-BE Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2017 Phase 2 EUCTR2017-001002-15-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 2 EUCTR2017-001002-15-BG Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States;
UCB Japan Co., Ltd
2019 Phase 3 JPRN-JapicCTI-194860 Japan, Asia except Japan, North America;
UCB Japan Co., Ltd.
2020 Phase 3 JPRN-JapicCTI-205414 Japan, Asia except Japan, North America, Europe;
Ultracet
Chung Shan Medical University
2008 Phase 4 NCT00647517 Taiwan;
Upadacitinib
AbbVie
2021 - NCT05094128 Germany;
2017 Phase 2 NCT03178487 Australia;Belgium;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2018 Phase 2;Phase 3 EUCTR2017-000431-14-SE Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-NL Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-HR Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-DE Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-PT Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-PL Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-HU Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-GB Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-FR Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-FI Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-ES Australia;Canada;Hungary;Japan;Korea, Republic of;New Zealand;Portugal;Spain;Switzerland;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-DK Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-CZ Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-BE Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Ustekinumab
Charite University, Berlin, Germany
2011 Phase 2 NCT01330901 Germany;
Charité Universitätsmedizin Berlin
2011 Phase 2 EUCTR2011-000844-56-DE Germany;
Vessel
Guangdong Provincial Hospital of Chinese Medicine
2007 Phase 1 study ChiCTR-TRC-13004564 China;
Voltaren resinat
Charité - Campus Mitte
2008 Phase 4 EUCTR2007-007637-39-DE Germany;
Xeljanz
Pfizer Inc.
2018 Phase 3 EUCTR2018-000226-58-CZ Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 3 EUCTR2018-000226-58-HU Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-FR Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-ES Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Yisaipu®
Nanfang Hospital of Southern Medical University
2017 Phase 4 NCT03411798 China;
Yuxuebi tablet
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
2021 Phase 4 NCT04934059 China;
double-blinded secukinumab
Novartis Pharmaceuticals
2018 Phase 4 NCT03350815 United States;
open-label secukinumab
Novartis Pharmaceuticals
2018 Phase 4 NCT03350815 United States;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
2010 Phase 3 EUCTR2010-019872-65-GB Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2013 - EUCTR2010-019872-65-LT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-SK Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
2011 Phase 3 EUCTR2010-019872-65-CZ Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-BE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 - EUCTR2010-019872-65-AT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-HU Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-FI Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-EE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
- - EUCTR2010-019872-65-DE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
0881
Wyeth Farma S.A.
2006 - EUCTR2006-002349-35-ES Spain;
Wyeth Pharmaceuticals France, Wyeth Research Division
2007 - EUCTR2006-001061-42-FI Denmark;Finland;Sweden;United Kingdom;
2006 Phase 4 EUCTR2006-001061-42-GB Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-SE Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-DK Denmark;Finland;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
146368
Celgene Corporation
2021 Phase 2 EUCTR2019-004108-37-DE Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States;
18F]Fluoride
VU Medical Center, department of Rheumatology
2018 Phase 4 EUCTR2017-004850-40-NL Netherlands;
331731-18-1
Abbott
- - EUCTR2014-004532-18-Outside-EU/EEA Japan;
42942019
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
2016 Phase 4 EUCTR2016-002061-54-IT Italy;
5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
2010 Phase 3 EUCTR2010-019872-65-GB Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2013 - EUCTR2010-019872-65-LT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-SK Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
2011 Phase 3 EUCTR2010-019872-65-CZ Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-BE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 - EUCTR2010-019872-65-AT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-HU Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-FI Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-EE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
- - EUCTR2010-019872-65-DE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
5057732
AMC
2014 - EUCTR2013-002860-19-NL Netherlands;
99mTc-rhAnnexin V-128
Advanced Accelerator Applications
2014 Phase 1/Phase 2 NCT02328027 Switzerland;
ABT-494
ABBVIE DEUTSCHLAND GMBH & CO. KG
2020 Phase 3 EUCTR2019-003229-12-IT Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Ukraine;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2020 Phase 3 EUCTR2019-003229-12-SK Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003229-12-HU Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003229-12-GB Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003229-12-ES Argentina;Australia;Brazil;Canada;China;Hungary;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-003229-12-DE Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-SE Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-NL Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-HR Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-DE Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-PT Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-PL Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-HU Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-GB Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-FR Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-FI Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-ES Australia;Canada;Hungary;Japan;Korea, Republic of;New Zealand;Portugal;Spain;Switzerland;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-DK Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-CZ Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-BE Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
ABY-035
Inmagene Biopharmaceuticals
2021 Phase 2 NCT04795141 Cayman Islands;
AIN457
NOVARTIS FARMA
2011 - EUCTR2010-024529-18-IT Belgium;Bulgaria;Canada;Germany;Italy;Mexico;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;
NOVARTIS FARMA S.P.A.
2015 Phase 3 EUCTR2013-005575-41-IT Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;United Kingdom;
Novartis Farma SpA
2013 Phase 3 EUCTR2013-001089-40-IT Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Novartis Farmacéutica, S.A.
2015 Phase 3 EUCTR2013-005575-41-ES Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001090-24-ES Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000046-35-ES Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
Novartis Pharma AG
2021 Phase 4 EUCTR2020-004284-98-GR Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;United States;
2021 Phase 4 EUCTR2020-004284-98-BG Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
2020 Phase 3 EUCTR2019-001177-90-SE Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
2020 Phase 3 EUCTR2019-001177-90-IT Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
2020 Phase 3 EUCTR2019-001177-90-GR Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
2020 Phase 3 EUCTR2019-001177-90-CZ Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
2020 Phase 3 EUCTR2019-001177-90-BG Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
- Phase 4 EUCTR2020-004284-98-PL Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
- Phase 4 EUCTR2020-004284-98-CZ Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
Novartis Pharma GmbH
2016 Phase 4 EUCTR2015-004575-74-DE Germany;
Novartis Pharma K.K.
2016 Phase 3 JPRN-JapicCTI-163241 -
Novartis Pharma Services AG
2016 Phase 3 EUCTR2015-005021-39-GB China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom;
2016 Phase 3 EUCTR2015-005021-39-CZ China;Czech Republic;Korea, Democratic People's Republic of;United Kingdom;
2015 Phase 3 EUCTR2013-005575-41-SK Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-PL Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-NO Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-NL Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-GR Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-GB Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-FI Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-DK Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-DE Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-CZ Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-BG Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2015 Phase 3 EUCTR2013-005575-41-AT Australia;Austria;Bulgaria;Canada;Czech Republic;Denmark;Finland;Germany;Greece;Italy;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001090-24-PT Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001090-24-NO Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001090-24-GR Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001090-24-GB Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001090-24-DE Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001090-24-BE Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001089-40-BG Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001089-40-BE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001090-24-CZ Belgium;Czech Republic;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001089-40-NL Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001089-40-GB Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000046-35-NL Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000046-35-GB Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000046-35-FI Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2012-000046-35-DE Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
2011 - EUCTR2010-024529-18-GB Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-DE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-BG Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-BE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2010 Phase 2 EUCTR2009-011591-30-GB Germany;Netherlands;United Kingdom;
2010 - EUCTR2009-011591-30-NL Germany;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011591-30-DE Germany;Netherlands;United Kingdom;
2009 - EUCTR2008-002631-33-NL Germany;Netherlands;United Kingdom;
2009 - EUCTR2008-002631-33-GB Germany;Netherlands;United Kingdom;
2008 - EUCTR2008-002631-33-DE Germany;Netherlands;United Kingdom;
Novartis Pharmaceuticals
2009 Phase 2 NCT00809159 Germany;Netherlands;United Kingdom;United States;
AIN457,
Novartis Pharma Services AG
2013 Phase 3 EUCTR2013-001089-40-DE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
AIN457A
Novartis Pharmaceuticals
2010 Phase 2 NCT01109940 Germany;Netherlands;United Kingdom;United States;
AIN457F
NOVARTIS FARMA
2012 Phase 3 EUCTR2012-000046-35-IT Austria;Canada;Czech Republic;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
ARCOXIA 90 mg comprimidos recubiertos con película
FUNDACIÓN ESPAÑOLA DE REUMATOLOGÍA (FER)
2010 - EUCTR2009-017309-12-ES Spain;
ARRY-371797
Array BioPharma Inc.
2009 - EUCTR2008-007510-30-PL Hungary;Poland;
2009 - EUCTR2008-007510-30-HU Hungary;Poland;
ARRY-371797, p38 inhibitor
Pfizer
2008 Phase 2 NCT00811499 Canada;United States;
AS
Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
2009 - ChiCTR-ONRC-11001565 -
Department of rheumatology of the Chinese PLA General Hospital
2015 - ChiCTR-IPR-15006753 China;
Guangdong Provincial Hospital of Chinese Medicine
2007 Phase 1 study ChiCTR-TRC-13004564 China;
PLA General Hospital
2018 - ChiCTR1800019227 China;
The First Affiliated Hospital of Suzhou University
2021 Phase 0 ChiCTR2100044377 China;
Abatacept
Charite University, Berlin, Germany
2008 Phase 2 NCT00558506 Germany;
Charité University Medicine
2007 - EUCTR2007-002967-28-DE Germany;
Aclasta
Cambridge University Hospitals NHS Foundation Trust
2007 - EUCTR2007-000087-25-GB United Kingdom;
Adalimumab
ABBOTT
2006 - EUCTR2005-004826-21-IT Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
AbbVie
2016 - NCT02750800 Hungary;
2014 - NCT02333383 Korea, Republic of;
2013 - NCT01768858 Austria;
Abbott
2010 Phase 3 NCT01114880 China;
2008 Phase 3 NCT00667355 Japan;
Abbott GmbH & Co. KG
2007 - EUCTR2005-004826-21-BE Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004826-21-DK Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-SE Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-IE Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-GR Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-GB Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-FI Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-ES Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-DE Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-AT Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
Abbott Japan Co., Ltd.
2008 Phase 3 JPRN-JapicCTI-080580 -
Abbott Laboratories
2006 - EUCTR2005-004826-21-NO Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
2008 - EUCTR2007-003358-27-DE Germany;
Chung Shan Medical University
2008 Phase 4 NCT02489760 Taiwan;
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly and Company
2021 Phase 3 NCT04527380 Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom;
2014 Phase 3 NCT01870284 Argentina;Belgium;Canada;Czech Republic;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Hvidovre University Hospital
2004 Phase 4 NCT00133315 Denmark;
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
Innovent Biologics (Suzhou) Co. Ltd.
2016 Phase 3 NCT02893254 -
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
Mianyang Hospital of Traditional Chinese Medicine
2021 Phase 4 ChiCTR2100044045 China;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Regionshospitalet Silkeborg
2010 Phase 4 NCT01174186 Denmark;
Universidade Nova de Lisboa
2015 Phase 4 NCT02492217 Portugal;
University Hospital, Tours
2013 Phase 4 NCT01895764 France;
Adalimumab (D2E7)
Abbott
2004 Phase 3 NCT00085644 United States;
2003 Phase 3 NCT00195819 Canada;United States;
Adalimumab (Humira)
Abbott
2006 Phase 3 NCT00478660 Austria;Belgium;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Norway;Spain;Sweden;Switzerland;United Kingdom;
Adalimumab 40 mg sc every other week
Charite University, Berlin, Germany
2005 Phase 2/Phase 3 NCT00235105 Germany;
Adalimumab and its biosimilars
Hanyang University Seoul Hospital
2022 Phase 4 NCT05164198 -
Adalimumab, Etanercept, Golimumab or infliximab
University Hospital, Montpellier
2012 - NCT01610947 France;
Alendronate
Göteborg University
2009 - NCT01104987 Sweden;
Anti TNF alpha agent
All India Institute of Medical Sciences, New Delhi
2011 - NCT01361542 India;
Anti TNF alpha therapy
All India Institute of Medical Sciences, New Delhi
2011 - NCT01361542 India;
Anti-(human tumor necrosis factor) immunoglobulin G (human-mouse monoclonal cA2 heavy chain)
Rheumazentrum Ruhrgebiet.
2006 Phase 4 EUCTR2005-002460-29-BE Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2005-002460-29-FI Belgium;Finland;Germany;United Kingdom;
2005 Phase 4 EUCTR2005-002460-29-GB Belgium;Finland;Germany;United Kingdom;
2005 - EUCTR2005-002460-29-DE Belgium;Finland;Germany;United Kingdom;
Anti-Human Interleukin-23 Monoclonal Antibody
SUN Pharmaceuticals Global FZE
2017 Phase 2 EUCTR2016-003936-19-HU Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003936-19-ES Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
Sun Pharma Global FZE
2018 Phase 3 EUCTR2018-001060-35-HU Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
2018 Phase 3 EUCTR2018-001060-35-ES Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
Anti-TNF
University Hospital, Bordeaux
2015 Phase 3 NCT02469753 France;Monaco;
Anti-TNF agents
Istanbul Physical Medicine Rehabilitation Training and Research Hospital
2019 - NCT04943237 Turkey;
Anti-TNF therapy (etanercept or adalimumab)
Imperial College London
2010 - NCT01060098 United Kingdom;
Anti-Tumor Necrosis Factor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
1999 Phase 2 NCT00000433 United States;
Apremilast
Celgene Corporation
2013 Phase 3 EUCTR2011-001555-37-EE Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-SK Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-SE Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-PL Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-NL Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-HU Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-GB Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-FR Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-ES Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-DE Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-CZ Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-BG Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-AT Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
Imperial College London
2009 Phase 2 NCT00944658 United Kingdom;
2009 - EUCTR2008-004229-40-GB United Kingdom;
Apremilast tablet 30 mg BID
Amgen
2012 Phase 3 NCT01583374 Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;United Kingdom;United States;
BAT1406
Bio-Thera Solutions
2016 Phase 3 NCT04135508 -
BCD-055
Biocad
2016 Phase 3 NCT02762812 Russian Federation;
BCD-085
Biocad
2018 Phase 3 NCT03447704 Russian Federation;
2016 Phase 2 NCT02763111 -
BDMARD treatment
Uppsala University
2005 - NCT02840695 -
BI 655066 90 mg/ml
Boehringer Ingelheim
2014 Phase 2 EUCTR2013-003666-13-IT Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
Boehringer Ingelheim España, S.A.
2013 Phase 2 EUCTR2013-003666-13-ES Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
Boehringer Ingelheim Finland Ky
2013 Phase 2 EUCTR2013-003666-13-FI Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
Boehringer Ingelheim Pharma GmbH & Co. KG
2014 Phase 2 EUCTR2013-003666-13-DE Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
Boehringer-Ingelheim bv
2014 Phase 2 EUCTR2013-003666-13-NL Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
SCS Boehringer Ingelheim Comm.V
2014 Phase 2 EUCTR2013-003666-13-BE Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
BI 730357
Boehringer Ingelheim RCV GmbH & Co KG
2020 Phase 2 EUCTR2019-001684-77-HU Belgium;Czechia;Georgia;Germany;Hungary;Korea, Republic of;Moldova, Republic of;Romania;Spain;Ukraine;United States;
BMS-188667
Charité University Medicine
2007 - EUCTR2007-002967-28-DE Germany;
BMS-986251
Bristol-Myers Squibb
2017 Phase 1/Phase 2 NCT03329885 Netherlands;
Bawei Shenqi Pill
Shanghai University of Traditional Chinese Medicine
2017 Phase 2/Phase 3 NCT04480359 China;
Bimekizumab
UCB Biopharma S.P.R.L.
2017 Phase 2 NCT03215277 Australia;Czechia;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2016 Phase 2 NCT02963506 Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States;
UCB Biopharma SPRL
2018 Phase 2 EUCTR2017-000957-37-NL Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-GR Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-DE Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-CZ Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2016-001102-42-GB Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001102-42-DE Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2017 Phase 2 EUCTR2016-001102-42-BG Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-001102-42-HU Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2016-001102-42-ES Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2016-001102-42-CZ Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
UCB Biopharma SRL
2020 Phase 3 NCT04436640 Belgium;Bulgaria;China;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 NCT03928743 Belgium;Bulgaria;China;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2017 Phase 2 NCT03355573 Bulgaria;Canada;Czechia;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States;
UCB Japan Co., Ltd
2019 Phase 3 JPRN-JapicCTI-194860 Japan, Asia except Japan, North America;
UCB Japan Co., Ltd.
2020 Phase 3 JPRN-JapicCTI-205414 Japan, Asia except Japan, North America, Europe;
Biologic DMARD
Seoul National University Hospital
2013 - NCT01965132 Korea, Republic of;
Biosimilar
McGill University Health Centre/Research Institute of the McGill University Health Centre
2018 - NCT03729674 Canada;
Opal Rheumatology Ltd.
2018 - NCT03470688 Australia;
Blood collection
CHU de Reims
2015 - NCT02809300 France;
Blood samples
Assistance Publique Hopitaux De Marseille
2017 - NCT03322618 France;
Blood sampling from infant
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood sampling from mother
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood sampling from umbilical cord
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Breast milk sampling
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02154425 France;Netherlands;Switzerland;United States;
CC-10004
Celgene Corporation
2013 Phase 3 EUCTR2011-001555-37-EE Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-SK Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-SE Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-PL Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-NL Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-HU Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-GB Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-FR Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-ES Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-DE Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-CZ Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-BG Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001555-37-AT Australia;Austria;Bulgaria;Canada;Czech Republic;Estonia;France;Germany;Hungary;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
Imperial College London
2009 - EUCTR2008-004229-40-GB United Kingdom;
CC-99677
Celgene
2021 Phase 2 NCT04947579 Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States;
CC-99677 30mg Capsule
Celgene Corporation
2021 Phase 2 EUCTR2019-004108-37-DE Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States;
CC-99677 60mg Capsule
Celgene Corporation
2021 Phase 2 EUCTR2019-004108-37-DE Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey;United States;
CDP870
SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
2010 Phase 3 EUCTR2009-011719-19-GB Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-FR Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
UCB BioSciences GmbH
2010 - EUCTR2009-011719-19-NL Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011719-19-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011719-19-CZ Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
UCB Biopharma SPRL
2018 Phase 2 EUCTR2017-000957-37-NL Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-GR Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-DE Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-CZ Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
CIMZIA certolizumab pegol 200 mg/ml solution for injection
UCB BIOSCIENCES GmbH
2016 Phase 3 EUCTR2015-001894-41-BG Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States;
2015 Phase 3 EUCTR2015-001894-41-HU Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States;
2015 Phase 3 EUCTR2015-001894-41-CZ Australia;Bulgaria;Canada;Czech Republic;Hungary;Poland;Russian Federation;Taiwan;United States;
CNTO 148
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-GB Belgium;Finland;Germany;United Kingdom;
2006 Phase 3 EUCTR2004-003299-12-BE Belgium;Finland;Germany;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2004-003299-12-FI Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2004-003299-12-DE Belgium;Finland;Germany;United Kingdom;
CP-690,550
Pfizer Inc.
2018 Phase 3 EUCTR2018-000226-58-CZ Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 3 EUCTR2018-000226-58-HU Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-GB Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-FR Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-ES Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-DE Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-BG Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-AT Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
CP-690,550-10
Pfizer Inc, 235 East 42nd Street, New York 10017
2013 - EUCTR2011-005689-39-HU Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
Pfizer Inc. 235 East 42nd Street, New York, 10017
2014 Phase 2 EUCTR2011-005689-39-SK Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2014 - EUCTR2011-005689-39-NL Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
2014 - EUCTR2011-005689-39-DE Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2013 Phase 2 EUCTR2011-005689-39-ES Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2013 - EUCTR2011-005689-39-CZ Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
CT-P13
Pfizer
2015 - NCT02605642 Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Spain;United Kingdom;
CTLA4Ig
Charité University Medicine
2007 - EUCTR2007-002967-28-DE Germany;
Cannabidiol tablet
King Christian 10th Hospital for Rheumatology
2018 Phase 2 EUCTR2017-004226-15-DK Denmark;
Cannabis
University Hospital, Clermont-Ferrand
2020 - NCT04402554 France;
Celebrex
Charite Universitaetsmedizin
2016 Phase 4 EUCTR2016-000615-33-DE Germany;
Celecoxib
Affiliated Hospital of Nanjing University of Chinese Medicine
2021 Phase 0 ChiCTR2100044284 China;
Charite University, Berlin, Germany
2016 Phase 4 NCT02758782 Germany;
Columbia University
2018 Phase 4 NCT03473665 United States;
Guangdong Provincial Hospital of Chinese Medicine
2021 Phase 0 ChiCTR2100042789 China;
2007 Phase 1 study ChiCTR-TRC-13004564 China;
Jiangsu Province Hospital of TCM
2019 - ChiCTR2000034142 China;
Pfizer
2003 Phase 3 NCT00648141 Germany;
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009 Phase 3 NCT00762463 China;
Zhixiang Huang
2016 Phase 4 NCT02638896 -
Celecoxib 200 milligrams
Pfizer
2002 Phase 4 NCT02528201 Norway;
Celecoxib 400 milligrams
Pfizer
2002 Phase 4 NCT02528201 Norway;
Celecoxib, Celebrex®
Sun Yat-sen University
2012 - NCT01709656 China;
Certolizumab
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
Certolizumab pegol
READE
2015 - EUCTR2015-002284-42-FI Finland;
UCB Biopharma S.P.R.L.
2017 Phase 2 NCT03215277 Australia;Czechia;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
Certolizumab pegol (CZP)
SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
2010 Phase 3 EUCTR2009-011719-19-GB Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-FR Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
UCB BioSciences GmbH
2010 - EUCTR2009-011719-19-NL Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011719-19-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011719-19-CZ Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
Certolizumab pegol / CIMZIA
UCB Biosciences Inc.
2014 Phase 1 EUCTR2013-003812-30-NL France;Germany;Netherlands;Switzerland;United States;
Cimzia
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Cimzia 200 mg solution for injection
UCB Biopharma SPRL
2018 Phase 2 EUCTR2017-000957-37-NL Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-GR Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-DE Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-CZ Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
Cimzia®
SCHWARZ BIOSCIENCES, GmbH, A Member of the UCB Group of Companies
2010 Phase 3 EUCTR2009-011719-19-GB Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-FR Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
UCB BioSciences GmbH
2010 - EUCTR2009-011719-19-NL Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011719-19-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011719-19-CZ Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;United Kingdom;
2010 - EUCTR2009-011719-19-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;France;Germany;Hungary;Italy;Mexico;Netherlands;United Kingdom;United States;
Conventional therapy users for the last 5 years
Istanbul Physical Medicine Rehabilitation Training and Research Hospital
2019 - NCT04943237 Turkey;
Cosentyx
Rigshospitalet - Glostrup
Afdeling for Rygkirurgi, Led- og Bindevævssygdomme
Novartis Pharma AG
2021 Phase 4 EUCTR2020-004284-98-GR Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;United States;
2021 Phase 4 EUCTR2020-004284-98-BG Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
- Phase 4 EUCTR2020-004284-98-PL Belgium;Brazil;Bulgaria;Colombia;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
- Phase 4 EUCTR2020-004284-98-CZ Belgium;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Egypt;Germany;Greece;Guatemala;India;Korea, Republic of;Malaysia;Mexico;Poland;Russian Federation;South Africa;Spain;Sweden;Turkey;United States;
Novartis Pharma GmbH
2016 Phase 4 EUCTR2015-004575-74-DE Germany;
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-001089-40-BE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
DMARDs
Janssen Research & Development, LLC
2015 - NCT02293681 China;
Diclofenac
Chinese PLA General Hospital
2010 Phase 1 study ChiCTR-ONRC-10000858 China;
Columbia University
2018 Phase 4 NCT03473665 United States;
Johnson & Johnson Taiwan Ltd
2008 Phase 4 NCT00766402 -
Pfizer
2003 Phase 3 NCT00648141 Germany;
Diclofenac 50 milligrams
Pfizer
2002 Phase 4 NCT02528201 Norway;
Diclofenac SR
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2009 Phase 3 NCT00762463 China;
Diclophenac
Charite University, Berlin, Germany
2008 Phase 4 NCT00715091 Germany;
Dronabinol capsule
King Christian 10th Hospital for Rheumatology
2018 Phase 2 EUCTR2017-004226-15-DK Denmark;
Drug treatment
University of Zurich
2004 Phase 2 NCT01038011 Switzerland;
E-Device
UCB Biopharma S.P.R.L.
2017 Phase 3 NCT03357471 United States;
ENIA11
Mycenax Biotech Inc.
2016 Phase 3 NCT02685904 Taiwan;
Enbrel
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
Pfizer
2011 - NCT01411215 China;
2009 - NCT01421303 Belgium;
2008 - NCT01188655 -
READE
2015 - EUCTR2015-002284-42-FI Finland;
WYETH LEDERLE
2009 - EUCTR2007-003096-39-IT Italy;
2006 - EUCTR2005-001549-41-IT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Wyeth Farma S.A.
2006 - EUCTR2006-002349-35-ES Spain;
Wyeth Pharmaceuticals B.V.
2009 - EUCTR2009-015515-40-NL Netherlands;
Wyeth Pharmaceuticals France
2008 - EUCTR2006-002748-27-HU France;Germany;Hungary;Netherlands;
2007 - EUCTR2006-002748-27-NL France;Germany;Hungary;Netherlands;
2007 - EUCTR2006-002748-27-DE France;Germany;Hungary;Netherlands;
2006 Phase 4 EUCTR2006-002748-27-FR France;Germany;Hungary;Netherlands;
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Enbrel (Etanercept)
Wyeth is now a wholly owned subsidiary of Pfizer
2004 Phase 4 NCT00444340 -
Enbrel (etanercept)
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Wyeth is now a wholly owned subsidiary of Pfizer
2007 Phase 3 NCT00434044 -
2006 Phase 4 NCT00410046 Denmark;Finland;Sweden;United Kingdom;
2002 Phase 3 NCT00421915 -
Enbrel plus Celebrex
Sun Yat-sen University
2014 Phase 4 NCT01934933 China;
Enbrel®
Norfolk & Norwich University Hospitals NHS Foundation Trust
2010 Phase 4 EUCTR2010-020913-10-GB United Kingdom;
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
Entecavir
Seoul National University Hospital
2012 Phase 3 NCT01694264 Korea, Republic of;
Etanercept
Amgen
2002 Phase 3 NCT00356356 United States;
AryoGen Pharmed Co.
2014 - NCT04582084 Iran, Islamic Republic of;
Charite University, Berlin, Germany
2002 Phase 2 NCT01289743 Germany;
Chung Shan Medical University
2008 Phase 4 NCT02489760 Taiwan;
Hvidovre University Hospital
2004 Phase 4 NCT00133315 Denmark;
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
Nanfang Hospital of Southern Medical University
2019 - ChiCTR1900025749 China;
Norfolk & Norwich University Hospitals NHS Foundation Trust
2010 Phase 4 EUCTR2010-020913-10-GB United Kingdom;
Pfizer
2020 - NCT04507763 Iraq;
2014 - NCT02202850 Belgium;
2009 Phase 4 NCT00910273 Italy;
2007 - NCT00544557 Germany;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2016 Phase 2/Phase 3 NCT02809781 China;
Sun Yat-sen University
2007 Phase 4 NCT02915354 China;
WYETH LEDERLE
2009 - EUCTR2007-003096-39-IT Italy;
2006 - EUCTR2005-001549-41-IT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Wyeth Farma S.A.
2006 - EUCTR2006-002349-35-ES Spain;
Wyeth Pharmaceuticals France, Wyeth Research Division
2007 - EUCTR2006-001061-42-FI Denmark;Finland;Sweden;United Kingdom;
2006 Phase 4 EUCTR2006-001061-42-GB Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-SE Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-DK Denmark;Finland;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-CZ Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Wyeth is now a wholly owned subsidiary of Pfizer
2006 Phase 4 NCT00873730 -
2006 Phase 4 NCT00458185 -
2005 Phase 4 NCT00247962 Australia;Austria;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Qatar;Saudi Arabia;Spain;Sweden;Switzerland;United Kingdom;
2005 - NCT00195416 Korea, Republic of;
2004 Phase 3 NCT00418548 -
2002 Phase 3 NCT00421980 Belgium;
Etanercept (50mg per week)
Nanfang Hospital of Southern Medical University
2019 Phase 4 NCT04077957 China;
Etanercept (50mg per week, for 2 weeks)
Nanfang Hospital of Southern Medical University
2019 Phase 4 NCT04077957 China;
Etanercept (50mg per week, for 4 weeks)
Nanfang Hospital of Southern Medical University
2019 Phase 4 NCT04077957 China;
Etanercept (Enbrel)
Wyeth is now a wholly owned subsidiary of Pfizer
2007 Phase 4 NCT00420238 France;Germany;Hungary;Netherlands;
Etanercept (Full-Dose)
Zhixiang Huang
2016 Phase 4 NCT02638896 -
Etanercept (Half-Dose)
Zhixiang Huang
2016 Phase 4 NCT02638896 -
Etanercept and its biosimilars
Hanyang University Seoul Hospital
2022 Phase 4 NCT05164198 -
Etoricoxib
Organon and Co
2011 - NCT01327638 -
2009 - NCT01077843 -
2006 - NCT01685424 United States;
Spanish Foundation of Rheumatology
2010 Phase 3 NCT01091675 Spain;
Eupatilin
Seoul National University Boramae Hospital
2021 Phase 4 NCT04885751 -
Faecal microbiota transplantation
Torkell Ellingsen
2022 Phase 2 NCT04924270 -
Fengshigutong Capsule plus Imrecoxib
Sun Yat-sen University
2016 Phase 4 NCT03932006 China;
Filgotinib
Galapagos NV
2019 Phase 2 NCT03926195 Belgium;Bosnia and Herzegovina;Bulgaria;Czechia;Estonia;Georgia;Latvia;Poland;Spain;Ukraine;
2017 Phase 2 NCT03117270 Belgium;Bulgaria;Czechia;Estonia;Poland;Spain;Ukraine;
Gilead Sciences
2020 Phase 3 NCT04483700 -
2020 Phase 3 NCT04483687 -
Focetria (Monovalent MF59-Adjuvanted vaccine)
Tel-Aviv Sourasky Medical Center
2009 Phase 2 NCT01006681 -
GLPG0634
Galapagos NV
2019 Phase 2 EUCTR2018-003933-14-LV Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-ES Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-EE Bulgaria;Czech Republic;Estonia;Latvia;Poland;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-CZ Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-BG Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Czechia;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-BE Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2017 Phase 2 EUCTR2016-003636-21-ES Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
2017 Phase 2 EUCTR2016-003636-21-EE Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
2017 Phase 2 EUCTR2016-003636-21-CZ Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
2017 Phase 2 EUCTR2016-003636-21-BG Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
2017 Phase 2 EUCTR2016-003636-21-BE Belgium;Bulgaria;Czech Republic;Estonia;Germany;Poland;Spain;Ukraine;
GP2017
Novartis Farmacéutica, S.A.
2017 Phase 3 EUCTR2017-000679-10-ES Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
Novartis Pharma AG
2019 Phase 3 EUCTR2017-000679-10-GR Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-SK Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-PT Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-PL Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-NL Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-FR Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Korea, Republic of;Mexico;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-CZ Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-GB Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-FI Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-DK Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-DE Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
GP2017 (adalimumab biosimilar)
Novartis Pharma K.K.
2018 Phase 3 JPRN-JapicCTI-184106 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Novartis Pharmaceuticals
2017 Phase 3 NCT03259074 Argentina;Australia;Belgium;Canada;Chile;Colombia;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
Ginger
Affiliated Hospital of Nanjing University of Chinese Medicine
2021 Phase 0 ChiCTR2100044284 China;
Gold
Dalian Blood Center
2018 - ChiCTR-DDD-17014196 China;
Golimumab
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-GB Belgium;Finland;Germany;United Kingdom;
Centocor, Inc.
2010 Phase 3 NCT01248793 China;
Charite University, Berlin, Germany
2016 Phase 4 NCT02758782 Germany;
Hanyang University Seoul Hospital
2022 Phase 4 NCT05164198 -
Janssen Biotech, Inc.
2009 - NCT01081717 United States;
Janssen Research & Development, LLC
2014 Phase 3 NCT02186873 Australia;Brazil;Canada;Germany;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Ukraine;United States;
Johnson & Johnson Private Limited
2019 Phase 4 NCT03733925 India;
Merck Sharp & Dohme Corp.
2012 Phase 4 NCT01668004 Netherlands;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Golimumab (CNTO 148)
Centocor, Inc.
2005 Phase 3 NCT00265083 Belgium;Canada;Finland;France;Germany;Korea, Republic of;Netherlands;Taiwan;United Kingdom;United States;
Golimumab Injection
MSD Pharmaceuticals LLC
2016 - NCT03557853 Russian Federation;
Golimumab Liquid in Vial
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-BE Belgium;Finland;Germany;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2004-003299-12-FI Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2004-003299-12-DE Belgium;Finland;Germany;United Kingdom;
Golimumab Pre-Filled Syringe
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-BE Belgium;Finland;Germany;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2004-003299-12-FI Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2004-003299-12-DE Belgium;Finland;Germany;United Kingdom;
Herpes Zoster Vaccine
University of Alabama at Birmingham
2016 Phase 2 NCT02538341 United States;
2013 Phase 2 NCT02538757 United States;
Human Anti-TNF IgG1 Monoclonal Antibody
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-GB Belgium;Finland;Germany;United Kingdom;
2006 Phase 3 EUCTR2004-003299-12-BE Belgium;Finland;Germany;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2004-003299-12-FI Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2004-003299-12-DE Belgium;Finland;Germany;United Kingdom;
Human Anti-TNFalfa
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-GB Belgium;Finland;Germany;United Kingdom;
2006 Phase 3 EUCTR2004-003299-12-BE Belgium;Finland;Germany;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2004-003299-12-FI Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2004-003299-12-DE Belgium;Finland;Germany;United Kingdom;
Human anti-TNFa monoclonal antibody
Janssen Biologics, BV
2014 Phase 3 EUCTR2014-000241-74-DE Australia;Brazil;Canada;Germany;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Ukraine;United States;
Human umbilical cord-derived MSCs
Shandong University
2011 Phase 1 NCT01420432 China;
Humira
Abbott GmbH & Co. KG
2007 - EUCTR2005-004826-21-BE Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-004826-21-DK Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-SE Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-IE Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-GR Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-GB Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-FI Austria;Belgium;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-ES Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-DE Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-004826-21-AT Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
Abbott Laboratories
2006 - EUCTR2005-004826-21-NO Austria;Denmark;Finland;Germany;Greece;Ireland;Italy;Norway;Spain;Sweden;United Kingdom;
Bio-Thera Solutions
2016 Phase 3 NCT04135508 -
Clinical Immunology and Rheumatology
2009 - EUCTR2008-006885-27-NL Netherlands;
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly and Company
2021 Phase 3 EUCTR2018-000681-10-CZ Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-GB Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DK Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Faculdade de Ciências Médicas da Universidade Nova de Lisboa
2014 Phase 4 EUCTR2013-004406-25-PT Portugal;
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Regionalhospital Silkeborg
2010 Phase 4 EUCTR2009-018085-35-DK Denmark;
Humira 40 mg/0.8 ml solution for injection
Abbott
- - EUCTR2014-004532-18-Outside-EU/EEA Japan;
Humira®
Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
2008 - EUCTR2007-003358-27-DE Germany;
Samsung Bioepis Co., Ltd.
2014 Phase 3 EUCTR2013-005013-13-BG Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-PL Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-LT Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
Hydroxychloroquine
Nanfang Hospital of Southern Medical University
2019 Phase 4 NCT04077957 China;
Hyrimoz
Novartis Pharma AG
2019 Phase 3 EUCTR2017-000679-10-GR Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-SK Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-PT Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-PL Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-NL Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2018 Phase 3 EUCTR2017-000679-10-CZ Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-FI Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-DK Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2017-000679-10-DE Argentina;Australia;Belgium;Canada;Chile;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
IBI303
Innovent Biologics (Suzhou) Co. Ltd.
2016 Phase 3 NCT02893254 -
Ibuprofen
School of Chinese Medicine Southern Medical University
2010 - ChiCTR-TRC-11001274 China;
Iguratimod
PLA General Hospital
2018 - ChiCTR1800019227 China;
Qilu Hospital of Shandong University
2021 Phase 4 ChiCTR2100043171 China;
Ilumetri
Sun Pharma Global FZE
2018 Phase 3 EUCTR2018-001060-35-HU Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
Indomethacin
Boehringer Ingelheim
2001 Phase 3 NCT02183168 -
Columbia University
2018 Phase 4 NCT03473665 United States;
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
2011 Phase 1+Phase 2 ChiCTR-TRC-11001417 China;
Infliximab
Association de Recherche Clinique en Rhumatologie
2003 Phase 3 NCT00439283 France;
Celltrion
2012 Phase 1 NCT01571206 Korea, Republic of;
2010 Phase 1 NCT01220518 Korea, Republic of;
Centocor, Inc.
2002 Phase 3 NCT00207701 -
Chiba University Hospital
2012 Phase 2 JPRN-UMIN000015297 Japan;
2012 Phase 2 JPRN-UMIN000007806 Japan;
Gu Jieruo
2008 Phase 4 NCT00936143 China;
Göteborg University
2003 - NCT01850121 Sweden;
Hvidovre University Hospital
2004 Phase 4 NCT00133315 Denmark;
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
Janssen Korea, Ltd., Korea
2007 - NCT00760669 Korea, Republic of;
2007 - NCT00724529 Korea, Republic of;
Janssen Research & Development, LLC
2015 - NCT02293681 China;
Merck Sharp & Dohme Corp.
2010 Phase 4 NCT01148901 Spain;
2009 Phase 3 NCT00844805 Austria;Belgium;Denmark;France;Germany;Hungary;Korea, Republic of;Russian Federation;Ukraine;United States;
2005 Phase 3 NCT00202865 Canada;
2004 Phase 4 NCT00779012 -
2004 - NCT00725543 -
2003 - NCT00818168 Germany;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Rheumazentrum Ruhrgebiet
2005 - NCT00237419 Belgium;Finland;France;Germany;Netherlands;United Kingdom;
Rheumazentrum Ruhrgebiet.
2006 Phase 4 EUCTR2005-002460-29-BE Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2005-002460-29-FI Belgium;Finland;Germany;United Kingdom;
2005 Phase 4 EUCTR2005-002460-29-GB Belgium;Finland;Germany;United Kingdom;
2005 - EUCTR2005-002460-29-DE Belgium;Finland;Germany;United Kingdom;
Schering-Plough France
2008 - EUCTR2006-001579-40-DK Denmark;France;Hungary;Spain;
2007 Phase 4 EUCTR2006-001579-40-HU Denmark;France;Hungary;Spain;
2007 Phase 4 EUCTR2006-001579-40-FR Denmark;France;Hungary;Spain;
2007 - EUCTR2006-001579-40-ES Denmark;France;Hungary;Spain;
University Hospital, Tours
2007 Phase 4 NCT00507403 France;
Infliximab (BCD-055)
Biocad
2015 Phase 1 NCT02359903 Belarus;Russian Federation;
Infliximab (Remicade)
Biocad
2015 Phase 1 NCT02359903 Belarus;Russian Federation;
Infliximab and MTX
Chinese University of Hong Kong
2005 Phase 4 NCT00432432 -
Infliximab biosimilar
Hanyang University Seoul Hospital
2022 Phase 4 NCT05164198 -
Intravenous infusion of MSCs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2016 Phase 2/Phase 3 NCT02809781 China;
Ixekizumab
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly & Company
2013 Phase 3 EUCTR2011-002325-22-GB Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-HU Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-ES Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-DE Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-BE Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Eli Lilly and Company
2021 Phase 3 NCT04527380 Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom;
2014 Phase 3 NCT01870284 Argentina;Belgium;Canada;Czech Republic;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States;
JS005
Shanghai Junshi Bioscience Co., Ltd.
2021 Phase 2 NCT05212051 China;
Jaktinib Hydrochloride Tablets
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020 Phase 2 NCT04507659 -
Jing Si Herbal Tea LIQUID PACKETS
Buddhist Tzu Chi General Hospital
2022 - NCT05257174 Taiwan;
KIN-1901
Kinevant Sciences GmbH
2019 Phase 1 NCT04205851 Canada;
Kunxian capsule
Gu Jieruo
2008 Phase 4 NCT00953979 China;
L04AA24
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
L04AB01
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
L04AB04
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
L04AB05
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
LSD
Universidade do Porto
2020 - NCT04386538 Portugal;
LY2439821
Eli Lilly & Company
2013 Phase 3 EUCTR2011-002325-22-GB Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-HU Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-ES Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-DE Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-BE Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Eli Lilly and Company
2021 Phase 3 EUCTR2018-000681-10-CZ Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-GB Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DK Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Leflunomide
The First Affiliated Hospital of Heilongjiang Chinese Medicine Colledge
2018 - ChiCTR-INR-17013574 China;
Loxoprofen sodium hydrogel patch
Sun Yat-sen University
2015 Phase 4 NCT03800797 China;
Loxoprofen sodium tablet
Sun Yat-sen University
2015 Phase 4 NCT03800797 China;
Lyophilized etanercept powder(Yisaipu)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2014 Phase 3 NCT04345458 China;
METHOTREXATE DISODIUM
CHRU de TOURS
2013 Phase 4 EUCTR2012-004939-23-FR France;
METOJECT
CHRU de TOURS
2013 Phase 4 EUCTR2012-004939-23-FR France;
MK-0663
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
2010 Phase 3 EUCTR2010-019872-65-GB Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2013 - EUCTR2010-019872-65-LT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-SK Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
2011 Phase 3 EUCTR2010-019872-65-CZ Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-BE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 - EUCTR2010-019872-65-AT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-HU Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-FI Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-EE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
- - EUCTR2010-019872-65-DE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
MK-3222
SUN Pharmaceuticals Global FZE
2017 Phase 2 EUCTR2016-003936-19-HU Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003936-19-ES Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
Sun Pharma Global FZE
2018 Phase 3 EUCTR2018-001060-35-HU Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
2018 Phase 3 EUCTR2018-001060-35-ES Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
MRNA COVD19 vaccine
Mayo Clinic
2021 Early Phase 1 NCT04839315 United States;
MSB11022
Fresenius Kabi SwissBioSim GmbH
2019 Phase 1 NCT04018599 United States;
MSC
Sun Yat-sen University
2012 - NCT01709656 China;
MTX
Department of rheumatology of the Chinese PLA General Hospital
2015 - ChiCTR-IPR-15006753 China;
MabThera 500
University Hospital of North Staffordshire
2006 Phase 2 EUCTR2005-005358-27-GB United Kingdom;
Meloxicam
Columbia University
2018 Phase 4 NCT03473665 United States;
Shanghai University of Traditional Chinese Medicine
2017 Phase 2/Phase 3 NCT04480359 China;
Meloxicam suppository
Boehringer Ingelheim
2001 Phase 3 NCT02183168 -
Meloxicam tablet
Boehringer Ingelheim
2001 Phase 3 NCT02183168 -
Methotrexate
Association de Recherche Clinique en Rhumatologie
2003 Phase 3 NCT00439283 France;
Charite University, Berlin, Germany
2003 Phase 2 NCT00243750 Germany;
Janssen Korea, Ltd., Korea
2007 - NCT00760669 Korea, Republic of;
Merck Sharp & Dohme Corp.
2010 - NCT01313858 Germany;
Nanfang Hospital of Southern Medical University
2019 Phase 4 NCT04077957 China;
University Hospital, Tours
2013 Phase 4 NCT01895764 France;
Methylprednisolone
Saratov State Medical University
2012 Phase 2 NCT01790022 Russian Federation;
Misoprostol
Korea Otsuka Pharmaceutical Co.,Ltd.
2007 Phase 3 NCT00576706 Korea, Republic of;
Monoclonal Antibody (MAb)
Eli Lilly & Company
2013 Phase 3 EUCTR2011-002325-22-GB Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-HU Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-ES Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-DE Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002325-22-BE Argentina;Belgium;Canada;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Méthotrexate Bellon Comprimé
CHRU-TOURS
2007 - EUCTR2006-005157-29-FR France;
N.A.
Boehringer Ingelheim
2014 Phase 2 EUCTR2013-003666-13-IT Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
NSAIDs
Janssen Research & Development, LLC
2015 - NCT02293681 China;
University Hospital, Bordeaux
2015 Phase 3 NCT02469753 France;Monaco;
NSAIDs and sulfasalazine
Chung Shan Medical University
2009 Phase 2 NCT02456363 Taiwan;
Nanocurcumin
Tabriz University of Medical Sciences
2017 Phase 2 NCT03140657 Iran, Islamic Republic of;
Naprosyn
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
2010 Phase 3 EUCTR2010-019872-65-GB Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2013 - EUCTR2010-019872-65-LT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-SK Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
2011 Phase 3 EUCTR2010-019872-65-CZ Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-BE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 - EUCTR2010-019872-65-AT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-HU Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-FI Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-EE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
- - EUCTR2010-019872-65-DE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Naprosysn
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
2010 Phase 3 EUCTR2010-019872-65-GB Austria;Belgium;Czech Republic;Estonia;Finland;Germany;Hungary;Lithuania;Slovakia;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2010-019872-65-CZ Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 Phase 3 EUCTR2010-019872-65-BE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2011 - EUCTR2010-019872-65-AT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-HU Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-FI Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019872-65-EE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
- - EUCTR2010-019872-65-DE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Naproxen
Merck Sharp & Dohme Corp.
2009 Phase 3 NCT00844805 Austria;Belgium;Denmark;France;Germany;Hungary;Korea, Republic of;Russian Federation;Ukraine;United States;
Naproxen 500 mg tablets (PN 200 minus omeprazole)
POZEN
2006 Phase 3 NCT00367211 United States;
Non-anti-TNF biologics
Janssen Biotech, Inc.
2009 - NCT01081717 United States;
None
Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
2009 - ChiCTR-ONRC-11001565 -
Normal saline
Inmagene Biopharmaceuticals
2021 Phase 2 NCT04795141 Cayman Islands;
NsNSAIDs
Organon and Co
2011 - NCT01327638 -
Observational study
Janssen Korea, Ltd., Korea
2007 - NCT00760669 Korea, Republic of;
Olsalazine
National Center for Research Resources (NCRR)
1996 Phase 2 NCT00004288 -
Oral
Pfizer
2008 Phase 2 NCT00811499 Canada;United States;
Orencia
Charité University Medicine
2007 - EUCTR2007-002967-28-DE Germany;
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
Originator
Opal Rheumatology Ltd.
2018 - NCT03470688 Australia;
Originator (legacy) drug
McGill University Health Centre/Research Institute of the McGill University Health Centre
2018 - NCT03729674 Canada;
Other COX-2 inhibitor
Organon and Co
2011 - NCT01327638 -
Other Cox-2 inhibitors
Organon and Co
2009 - NCT01077843 -
Other Non-selective NSAIDs
Organon and Co
2009 - NCT01077843 -
Oxygen
Shenzhen Second People's Hospital
2021 - ChiCTR2100042477 China;
PN 200 tablets (500 mg naproxen and 20 mg omeprazole)
POZEN
2006 Phase 3 NCT00367211 United States;
Pamidronate
Bnai Zion Medical Center
2014 Phase 4 NCT02313727 Israel;
Parecoxib
Peking Union Medical College Hospital
2014 - ChiCTR1800014846 China;
Part I - etoricoxib
Organon and Co
2010 Phase 3 NCT01208207 Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Part I- naproxen
Organon and Co
2010 Phase 3 NCT01208207 Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Part II- etoricoxib
Organon and Co
2010 Phase 3 NCT01208207 Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Part II- naproxen
Organon and Co
2010 Phase 3 NCT01208207 Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
Placebo
UCB Japan Co., Ltd
2019 Phase 3 JPRN-JapicCTI-194860 Japan, Asia except Japan, North America;
Prednisolone
Charite University, Berlin, Germany
2002 Phase 2/Phase 3 NCT00244166 Germany;
Prefilled liquid etanercept(Yisaipu)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2014 Phase 3 NCT04345458 China;
REMICADE 100 mg polvo para concentrado para solución para perfusión
Schering Plough, S.A
2010 - EUCTR2009-016587-36-ES Spain;
REMSIMA - 100 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLANCONCINO (VETRO) - 1 FLACONCINO
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
2016 Phase 4 EUCTR2016-002061-54-IT Italy;
ROACTEMRA 20 mg/ml, concentrado para solución para perfusión
F. Hoffmann-La Roche Ltd.
2010 - EUCTR2009-017488-40-ES Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-ES Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
RTNV148B IgG
Centocor BV
2006 Phase 3 EUCTR2004-003299-12-GB Belgium;Finland;Germany;United Kingdom;
2006 Phase 3 EUCTR2004-003299-12-BE Belgium;Finland;Germany;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2004-003299-12-FI Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2004-003299-12-DE Belgium;Finland;Germany;United Kingdom;
Rebamipide
Korea Otsuka Pharmaceutical Co.,Ltd.
2007 Phase 3 NCT00576706 Korea, Republic of;
Seoul National University Boramae Hospital
2021 Phase 4 NCT04885751 -
Recombinant TNF-a receptor: IgG Fc fusion protein
Zhejiang Hisun Pharmaceutical Co. Ltd.
2018 - NCT03636984 -
Recombinant human monoclonal antibody to Il-17 of the IgG1-k-class
Novartis Pharma Services AG
2010 Phase 2 EUCTR2009-011591-30-GB Germany;Netherlands;United Kingdom;
2010 - EUCTR2009-011591-30-NL Germany;Netherlands;United Kingdom;United States;
2010 - EUCTR2009-011591-30-DE Germany;Netherlands;United Kingdom;
2009 - EUCTR2008-002631-33-NL Germany;Netherlands;United Kingdom;
2009 - EUCTR2008-002631-33-GB Germany;Netherlands;United Kingdom;
2008 - EUCTR2008-002631-33-DE Germany;Netherlands;United Kingdom;
Remicade
Merck Sharp & Dohme Corp.
2005 Phase 4 NCT00778869 -
2004 Phase 4 NCT00779935 -
READE
2015 - EUCTR2015-002284-42-FI Finland;
Rheumazentrum Ruhrgebiet.
2006 Phase 4 EUCTR2005-002460-29-BE Belgium;Finland;Germany;United Kingdom;
2006 - EUCTR2005-002460-29-FI Belgium;Finland;Germany;United Kingdom;
2005 Phase 4 EUCTR2005-002460-29-GB Belgium;Finland;Germany;United Kingdom;
2005 - EUCTR2005-002460-29-DE Belgium;Finland;Germany;United Kingdom;
Schering-Plough France
2008 - EUCTR2006-001579-40-DK Denmark;France;Hungary;Spain;
2007 Phase 4 EUCTR2006-001579-40-HU Denmark;France;Hungary;Spain;
2007 Phase 4 EUCTR2006-001579-40-FR Denmark;France;Hungary;Spain;
2007 - EUCTR2006-001579-40-ES Denmark;France;Hungary;Spain;
Remicade 100 mg pulver til konsentrat til infusjonsvæske, oppløsning
Diakonhjemmet Hospital AS
2014 - EUCTR2014-002056-40-NO Norway;
Remicade®
Biocad
2016 Phase 3 NCT02762812 Russian Federation;
Remsima 100 mg pulver til konsentrat til infusjonsvæske, oppløsning
Diakonhjemmet Hospital AS
2014 - EUCTR2014-002056-40-NO Norway;
RhuTNFR:Fc
Wyeth Pharmaceuticals France, Wyeth Research Division
2007 - EUCTR2006-001061-42-FI Denmark;Finland;Sweden;United Kingdom;
2006 Phase 4 EUCTR2006-001061-42-GB Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-SE Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-DK Denmark;Finland;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-CZ Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Rinvoq
AbbVie Deutschland GmbH & Co. KG
2020 Phase 3 EUCTR2019-003229-12-SK Argentina;Australia;Brazil;Canada;China;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;New Zealand;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Risankizumab
AbbVie
2014 Phase 2 NCT02047110 Belgium;Finland;France;Germany;Hong Kong;Italy;Korea, Republic of;Netherlands;Spain;Taiwan;United States;
Rituximab
Charite University, Berlin, Germany
2007 Phase 2/Phase 3 NCT00432653 Germany;
Rituximab/ Mabthera
Charité Universitaetsmedizin
2006 - EUCTR2006-002306-64-DE Germany;
Ro 487-533/F01
F. Hoffmann-La Roche Ltd.
2011 Phase 3 EUCTR2009-017488-40-BE Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-017488-40-GB Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-SK Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-DK Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-DE Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-CZ Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-BG Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
Ro 487-5733/F01
F. Hoffmann-La Roche Ltd.
2011 Phase 2;Phase 3 EUCTR2009-017443-34-BE Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2011 - EUCTR2009-017443-34-DE Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
2011 - EUCTR2009-017443-34-BG Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 Phase 2;Phase 3 EUCTR2009-017443-34-GB Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-SK Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-CZ Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
Ro 487-7533/F01
F. Hoffmann-La Roche Ltd.
2010 - EUCTR2009-017488-40-LT Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-LT Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
Ro45-2294
Charité Universitaetsmedizin
2006 - EUCTR2006-002306-64-DE Germany;
RoActemra
F. Hoffmann-La Roche Ltd.
2010 - EUCTR2009-017488-40-IT Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-IT Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
RoActemra®
F. Hoffmann-La Roche Ltd.
2011 Phase 3 EUCTR2009-017488-40-BE Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2011 Phase 2;Phase 3 EUCTR2009-017443-34-BE Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2011 - EUCTR2009-017443-34-DE Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
2011 - EUCTR2009-017443-34-BG Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 Phase 3 EUCTR2009-017488-40-GB Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 Phase 2;Phase 3 EUCTR2009-017443-34-GB Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-SK Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-LT Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-DK Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-DE Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-CZ Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-BG Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-SK Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-LT Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-CZ Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
Rosuvastatin
Diakonhjemmet Hospital
2013 - NCT01389388 Norway;
SAR153191
Sanofi-aventis Recherche & Développement
2010 Phase 2 EUCTR2009-016068-35-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 Phase 2 EUCTR2009-016068-35-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-NL Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-LT Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
2010 - EUCTR2009-016068-35-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Lithuania;Netherlands;Spain;
sanofi-aventis Recherche & Développement
2010 Phase 3 EUCTR2010-019263-11-FR Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
2010 Phase 3 EUCTR2010-019263-11-ES Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
2010 Phase 3 EUCTR2010-019263-11-BE Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
2010 - EUCTR2010-019263-11-LT Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
2010 - EUCTR2010-019263-11-HU Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
2010 - EUCTR2010-019263-11-CZ Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
2010 - EUCTR2010-019263-11-AT Austria;Belgium;Czech Republic;France;Hungary;Lithuania;Spain;
SB4 (etanercept biosimilar)
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
SB5
Samsung Bioepis Co., Ltd
2015 - EUCTR2014-004887-39-PL Poland;
Samsung Bioepis Co., Ltd.
2014 Phase 3 EUCTR2013-005013-13-BG Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-PL Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-LT Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
2014 - EUCTR2013-005013-13-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
SHR-1314
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2021 Phase 2/Phase 3 NCT04840485 China;
SHR0302
Jiangsu HengRui Medicine Co., Ltd.
2020 Phase 2/Phase 3 NCT04481139 China;
SUNPG1622 I dose
Sun Pharmaceutical Industries Limited
2017 Phase 2 NCT02980705 Hungary;Poland;Spain;United States;
Salicylazosulfapyridine
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
2011 Phase 1+Phase 2 ChiCTR-TRC-11001417 China;
Sarilumab
Sanofi
2010 Phase 2 NCT01118728 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Hungary;Lithuania;Netherlands;Poland;Spain;United States;
2010 Phase 2 NCT01061723 Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Hungary;Lithuania;Netherlands;Poland;Spain;Turkey;United States;
Secukinumab
NOVARTIS FARMA
2011 - EUCTR2010-024529-18-IT Belgium;Bulgaria;Canada;Germany;Italy;Mexico;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;
Novartis Farma SpA
2013 Phase 3 EUCTR2013-001089-40-IT Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Novartis Pharma K.K.
2018 Phase 3 JPRN-JapicCTI-184106 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-001089-40-BG Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001089-40-NL Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001089-40-GB Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2013-001089-40-DE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-GB Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-DE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-BG Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2011 - EUCTR2010-024529-18-BE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Novartis Pharmaceuticals
2022 - NCT05155098 -
2019 Phase 3 NCT04156620 Belgium;Brazil;Bulgaria;Colombia;Czechia;Greece;Guatemala;India;Italy;Korea, Republic of;Malaysia;Philippines;Poland;Russian Federation;Sweden;Thailand;Turkey;United States;
2017 Phase 3 NCT03259074 Argentina;Australia;Belgium;Canada;Chile;Colombia;Czechia;Denmark;Finland;France;Germany;Greece;Israel;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;Turkey;United Kingdom;United States;
2016 Phase 3 NCT02896127 China;Czech Republic;Czechia;Korea, Republic of;United Kingdom;
2015 Phase 3 NCT02159053 Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Russian Federation;Slovakia;Spain;Switzerland;United Kingdom;United States;
2014 Phase 3 NCT02008916 Belgium;Czech Republic;Czechia;Germany;Greece;Mexico;Norway;Portugal;Russian Federation;Spain;Sweden;United Kingdom;United States;
2013 Phase 3 NCT01863732 Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Secukinumab (150 mg)
Novartis Pharmaceuticals
2012 Phase 3 NCT01649375 Austria;Canada;Czech Republic;Czechia;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
2011 Phase 3 NCT01358175 Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Secukinumab (75 mg)
Novartis Pharmaceuticals
2012 Phase 3 NCT01649375 Austria;Canada;Czech Republic;Czechia;Finland;Germany;Italy;Netherlands;Russian Federation;Singapore;Spain;Switzerland;United Kingdom;United States;
2011 Phase 3 NCT01358175 Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Secukinumab (AIN457) 150 mg s.c.
Novartis Pharmaceuticals
2016 Phase 4 NCT02763046 Germany;
Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
Novartis Pharmaceuticals
2016 Phase 3 NCT02750592 Japan;
Secukinumab 150 mg/1 ml Solution for injection
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-001089-40-BE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Secukinumab 150 milligram [Cosentyx]
Professor Mikkel Østergaard
2019 Phase 4 NCT03639740 Denmark;
Secukinumab 75 mg/0.5 ml Solution for injection
Novartis Pharma Services AG
2014 Phase 3 EUCTR2013-001089-40-BE Belgium;Bulgaria;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
Simponi
Charite Universitaetsmedizin
2016 Phase 4 EUCTR2016-000615-33-DE Germany;
Chinese University of Hong Kong
2010 Phase 4 NCT01212653 China;
MERCK SHARP & DOHME B.V.
2012 Phase 4 EUCTR2012-002458-21-NL Netherlands;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Simponi®
Merck Sharp & Dohme Corp.
2010 - NCT01313858 Germany;
Sodium chloride
Chinese University of Hong Kong
2010 Phase 4 NCT01212653 China;
Stelara
Charité Universitätsmedizin Berlin
2011 Phase 2 EUCTR2011-000844-56-DE Germany;
Sulfasalazine
Nanchang Hongdu Hospital of TCM
2020 - ChiCTR2000038277 China;
Nanfang Hospital of Southern Medical University
2019 Phase 4 NCT04077957 China;
School of Chinese Medicine Southern Medical University
2010 - ChiCTR-TRC-11001274 China;
Sun Yat-sen University
2008 Phase 2/Phase 3 NCT00889694 -
WYETH LEDERLE
2006 - EUCTR2005-001549-41-IT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Zhixiang Huang
2016 Phase 4 NCT02638896 -
Sulfasalazine, SSZ
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-CZ Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Sulphasalazine (SSZ)
Wyeth is now a wholly owned subsidiary of Pfizer
2005 Phase 4 NCT00247962 Australia;Austria;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Qatar;Saudi Arabia;Spain;Sweden;Switzerland;United Kingdom;
Sulphasalazine 500 mg En-Tabs
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-CZ Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
Systemic non-biological treatments
Janssen Biotech, Inc.
2009 - NCT01081717 United States;
TA-650 (Infliximab)
Mitsubishi Tanabe Pharma Corporation
- Phase 3 JPRN-JapicCTI-070346 -
THA
99 Huaihai Road West, Xuzhou, Jiangsu, China
2019 - ChiCTR1900025635 China;
TNF alpha
Chung Shan Medical University
2009 Phase 2 NCT02456363 Taiwan;
TNF blockers (infliximab, adalimumab, etanercept)
University of Sao Paulo
2008 Phase 4 NCT01072058 Brazil;
TNF-a antagonists, non-TNFs, DMARD non-biologics
Biologics & Biosimilars Collective Intelligence Consortium
2012 - NCT02922192 -
TNF-alpha antagonists
Assistance Publique - Hôpitaux de Paris
2004 - NCT00224562 France;
TNF-inhibition
Region Skane
2019 - NCT03839862 Sweden;
TNFR:Fc
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
Wyeth Pharmaceuticals France, Wyeth Research Division
2007 - EUCTR2006-001061-42-FI Denmark;Finland;Sweden;United Kingdom;
2006 Phase 4 EUCTR2006-001061-42-GB Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-SE Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-DK Denmark;Finland;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-CZ Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
TNR-001
Wyeth Pharmaceuticals France, Wyeth Research Division
2007 - EUCTR2006-001061-42-FI Denmark;Finland;Sweden;United Kingdom;
2006 Phase 4 EUCTR2006-001061-42-GB Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-SE Denmark;Finland;Sweden;United Kingdom;
2006 - EUCTR2006-001061-42-DK Denmark;Finland;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GR Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3;Phase 4 EUCTR2005-001549-41-GB Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 Phase 3 EUCTR2005-001549-41-IE Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-SE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-PT Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-FI Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DK Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-DE Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-001549-41-CZ Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-HU Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 Phase 3;Phase 4 EUCTR2005-001549-41-ES Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2005-001549-41-AT Austria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Portugal;Spain;Sweden;United Kingdom;
TNR-001, TNFR:FC
Wyeth Farma S.A.
2006 - EUCTR2006-002349-35-ES Spain;
TOFACITINIB CITRATE
Pfizer Inc, 235 East 42nd Street, New York 10017
2013 - EUCTR2011-005689-39-HU Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
Pfizer Inc.
2018 Phase 3 EUCTR2018-000226-58-CZ Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc. 235 East 42nd Street, New York, 10017
2014 Phase 2 EUCTR2011-005689-39-SK Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2014 - EUCTR2011-005689-39-NL Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
2014 - EUCTR2011-005689-39-DE Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2013 Phase 2 EUCTR2011-005689-39-ES Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2013 - EUCTR2011-005689-39-CZ Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 3 EUCTR2018-000226-58-HU Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-GB Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-FR Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-ES Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-DE Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-BG Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-AT Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Taltz (80 mg solution for injection in pre-filled syringe)
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2020 Phase 3 EUCTR2018-000681-10-IT Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Eli Lilly and Company
2021 Phase 3 EUCTR2018-000681-10-CZ Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-GB Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DK Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
2020 Phase 3 EUCTR2018-000681-10-DE Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-NL Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-FR Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2018-000681-10-BE Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Tapering or discontinuation of etanercept
Second Affiliated Hospital, School of Medicine, Zhejiang University
2012 - NCT03880968 -
Technetium labelled glucosamine
University of Sydney
2012 - NCT01789151 Australia;
Terbinafine Tablets
Oregon Health and Science University
2021 Early Phase 1 NCT05119712 United States;
Thalidomide
Chinese PLA General Hospital
2010 Phase 1 study ChiCTR-ONRC-10000858 China;
Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
2009 - ChiCTR-ONRC-11001846 -
Shanghai Pharmaceuticals Holding Co., Ltd
2013 Phase 2 NCT02201043 China;
The General Hospital of People's Liberation Army
2013 Phase 2 study ChiCTR-TRC-13003449 China;
Tildrakizumab
SUN Pharmaceuticals Global FZE
2017 Phase 2 EUCTR2016-003936-19-HU Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
2017 Phase 2 EUCTR2016-003936-19-ES Germany;Hungary;Mexico;Poland;Spain;United Kingdom;United States;
Tildrakizumab 100 mg/ml
Sun Pharma Global FZE
2018 Phase 3 EUCTR2018-001060-35-HU Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
2018 Phase 3 EUCTR2018-001060-35-ES Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine;United States;
Tocilizumab
F. Hoffmann-La Roche Ltd.
2010 - EUCTR2009-017488-40-LT Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017488-40-IT Belgium;Bulgaria;Czech Republic;Denmark;Germany;Italy;Lithuania;Spain;United Kingdom;
2010 - EUCTR2009-017443-34-LT Belgium;Bulgaria;Czech Republic;Germany;Italy;Lithuania;Spain;United Kingdom;
Hoffmann-La Roche
2010 Phase 3 NCT01209702 Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Germany;India;Italy;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
2010 Phase 3 NCT01209689 Australia;Belgium;Brazil;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;India;Italy;Lithuania;Netherlands;Poland;Slovakia;South Africa;Spain;United Kingdom;United States;
Tofacitinib
Pfizer
2018 Phase 3 NCT03502616 Australia;Bulgaria;Canada;China;Czechia;France;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United States;
2013 Phase 2 NCT01786668 Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Poland;Russian Federation;Spain;Taiwan;United States;
Tofacitinib XR
Pfizer
2021 - NCT04876781 -
Total Glucosides Paeony Capsules
Sun Yat-sen University
2011 Phase 4 NCT01517620 China;
Tramadol /acetaminophen
Johnson & Johnson Taiwan Ltd
2008 Phase 4 NCT00766402 -
Tripterygium
Sun Yat-sen University
2008 Phase 2/Phase 3 NCT00889694 -
Tripterygium Wilfordii
Jiangsu Provincial Hospital of Traditional Chinese Medicine
2011 - ChiCTR-TRC-11001193 China;
UCB4940
UCB BIOPHARMA SRL
2018 Phase 2 EUCTR2017-001002-15-DE Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States;
UCB BIOSCIENCES GmbH
2017 Phase 2 EUCTR2017-001002-15-HU Hungary;
UCB Biopharma SPRL
2019 Phase 3 EUCTR2017-003065-95-FR Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-ES Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2017-000957-37-NL Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-001002-15-ES Germany;Hungary;Spain;
2017 Phase 2 EUCTR2017-000957-37-GR Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-DE Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2017-000957-37-CZ Australia;Czech Republic;Germany;Greece;Moldova, Republic of;Netherlands;Poland;Russian Federation;United States;
2017 Phase 2 EUCTR2016-001102-42-GB Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2017 Phase 2 EUCTR2016-001102-42-DE Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2017 Phase 2 EUCTR2016-001102-42-BG Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-001102-42-HU Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2016-001102-42-ES Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2016 Phase 2 EUCTR2016-001102-42-CZ Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States;
UCB Biopharma SRL
2020 Phase 3 EUCTR2019-004163-47-HU Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004163-47-GB Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004163-47-DE Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004163-47-CZ Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004163-47-BG Belgium;Bulgaria;China;Czech Republic;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-NL Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-HU Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-GB Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-DE Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-CZ Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-BG Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2019 Phase 3 EUCTR2017-003065-95-BE Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hungary;Japan;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
2017 Phase 2 EUCTR2017-001002-15-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain;
2017 Phase 2 EUCTR2017-001002-15-BG Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Russian Federation;Spain;Ukraine;United States;
UCB Japan Co., Ltd
2019 Phase 3 JPRN-JapicCTI-194860 Japan, Asia except Japan, North America;
UCB Japan Co., Ltd.
2020 Phase 3 JPRN-JapicCTI-205414 Japan, Asia except Japan, North America, Europe;
Ultracet
Chung Shan Medical University
2008 Phase 4 NCT00647517 Taiwan;
Upadacitinib
AbbVie
2021 - NCT05094128 Germany;
2017 Phase 2 NCT03178487 Australia;Belgium;Canada;Croatia;Czechia;Denmark;Finland;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2018 Phase 2;Phase 3 EUCTR2017-000431-14-SE Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-NL Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-HR Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2018 Phase 2;Phase 3 EUCTR2017-000431-14-DE Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-PT Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-PL Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-HU Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-GB Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-FR Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-FI Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-ES Australia;Canada;Hungary;Japan;Korea, Republic of;New Zealand;Portugal;Spain;Switzerland;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-DK Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-CZ Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2017-000431-14-BE Australia;Belgium;Canada;Croatia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Ustekinumab
Charite University, Berlin, Germany
2011 Phase 2 NCT01330901 Germany;
Charité Universitätsmedizin Berlin
2011 Phase 2 EUCTR2011-000844-56-DE Germany;
Vessel
Guangdong Provincial Hospital of Chinese Medicine
2007 Phase 1 study ChiCTR-TRC-13004564 China;
Voltaren resinat
Charité - Campus Mitte
2008 Phase 4 EUCTR2007-007637-39-DE Germany;
Xeljanz
Pfizer Inc.
2018 Phase 3 EUCTR2018-000226-58-CZ Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2018 Phase 3 EUCTR2018-000226-58-HU Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-FR Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000226-58-ES Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hungary;Israel;Korea, Republic of;Poland;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Yisaipu®
Nanfang Hospital of Southern Medical University
2017 Phase 4 NCT03411798 China;
Yuxuebi tablet
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
2021 Phase 4 NCT04934059 China;
double-blinded secukinumab
Novartis Pharmaceuticals
2018 Phase 4 NCT03350815 United States;
open-label secukinumab
Novartis Pharmaceuticals
2018 Phase 4 NCT03350815 United States;